Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

<!DOCTYPE html> <html lang="en-US"> <head> <meta charset="UTF-8" /> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="viewport" content="width=device-width, initial-scale=1" /> <link data-minify="1" rel="stylesheet" href="https://www.ipsen.com/wp-content/cache/min/0/npm/bootstrap-icons@1.9.1/font/bootstrap-icons.css?ver=1739443667">  <script async src="https://www.googletagmanager.com/gtag/js?id=AW-16501157862"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'AW-16501157862'); </script>  <script type="text/javascript"> _linkedin_partner_id = "5855114"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script> <script type="text/javascript"> (function(l) { if (!l){window.lintrk = function(a,b){window.lintrk.q.push([a,b])}; window.lintrk.q=[]} var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = https://snap.licdn.com/li.lms-analytics/insight.min.js; s.parentNode.insertBefore(b, s);})(window.lintrk); </script> <noscript> <img height="1" width="1" style="display:none;" alt="" src=https://px.ads.linkedin.com/collect/?pid=5855114&fmt=gif /> </noscript>    <meta name='robots' content='index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1' /> <style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style> <link rel="alternate" hreflang="en" href="https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/" /> <link rel="alternate" hreflang="fr" href="https://www.ipsen.com/fr/press-releases/bylvay-odevixibat-montre-une-amelioration-soutenue-en-termes-de-severite-des-demangeaisons-et-de-taux-dacides-biliaires-seriques-chez-les-patients-atteints-de-cifp-et-du-sag-2982434/" /> <link rel="alternate" hreflang="x-default" href="https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/" />  <title>Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS</title> <link rel="preload" as="font" href="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/fonts/Lato-Bold.ttf" crossorigin> <link rel="preload" as="font" href="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/fonts/Lato-Light.ttf" crossorigin> <link rel="preload" as="font" href="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/fonts/Lato-Regular.ttf" crossorigin> <link rel="preload" as="font" href="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/fonts/Lato-Semibold.ttf" crossorigin><link rel="preload" data-rocket-preload as="image" href="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/12/07162335/Latest_Ipsen-logo_168x48.svg" fetchpriority="high"> <link rel="canonical" href="https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/" /> <meta property="og:locale" content="en_US" /> <meta property="og:type" content="article" /> <meta property="og:title" content="Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS" /> <meta property="og:url" content="https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/" /> <meta property="og:site_name" content="Global" /> <meta property="og:image" content="https://ml-eu.globenewswire.com/media/YWMwMjE1MDctMmQxNC00MTU1LWI1MmMtZmMxYjllOGJiMmMzLTEyNjgxMTY=/tiny/Ipsen-Pharma.png" /> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:site" content="@ipsengroup" /> <meta name="twitter:label1" content="Est. reading time" /> <meta name="twitter:data1" content="15 minutes" /> <script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"NewsArticle","@id":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/#article","isPartOf":{"@id":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/"},"author":{"name":"IPSEN","@id":"https://www.ipsen.com/#/schema/person/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS","datePublished":"2024-11-18T06:00:00+00:00","dateModified":"2024-11-18T06:00:00+00:00","mainEntityOfPage":{"@id":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/"},"wordCount":3110,"publisher":{"@id":"https://www.ipsen.com/#organization"},"image":{"@id":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/#primaryimage"},"thumbnailUrl":"https://ml-eu.globenewswire.com/media/YWMwMjE1MDctMmQxNC00MTU1LWI1MmMtZmMxYjllOGJiMmMzLTEyNjgxMTY=/tiny/Ipsen-Pharma.png","articleSection":["Corporate","Rare Diseases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/","url":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/","name":"Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS","isPartOf":{"@id":"https://www.ipsen.com/#website"},"primaryImageOfPage":{"@id":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/#primaryimage"},"image":{"@id":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/#primaryimage"},"thumbnailUrl":"https://ml-eu.globenewswire.com/media/YWMwMjE1MDctMmQxNC00MTU1LWI1MmMtZmMxYjllOGJiMmMzLTEyNjgxMTY=/tiny/Ipsen-Pharma.png","datePublished":"2024-11-18T06:00:00+00:00","dateModified":"2024-11-18T06:00:00+00:00","breadcrumb":{"@id":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/#primaryimage","url":"https://ml-eu.globenewswire.com/media/YWMwMjE1MDctMmQxNC00MTU1LWI1MmMtZmMxYjllOGJiMmMzLTEyNjgxMTY=/tiny/Ipsen-Pharma.png","contentUrl":"https://ml-eu.globenewswire.com/media/YWMwMjE1MDctMmQxNC00MTU1LWI1MmMtZmMxYjllOGJiMmMzLTEyNjgxMTY=/tiny/Ipsen-Pharma.png"},{"@type":"BreadcrumbList","@id":"https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.ipsen.com/"},{"@type":"ListItem","position":2,"name":"Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS"}]},{"@type":"WebSite","@id":"https://www.ipsen.com/#website","url":"https://www.ipsen.com/","name":"Global","description":"","publisher":{"@id":"https://www.ipsen.com/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://www.ipsen.com/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https://www.ipsen.com/#organization","name":"IPSEN","url":"https://www.ipsen.com/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://www.ipsen.com/#/schema/logo/image/","url":"https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/12/07162335/Latest_Ipsen-logo_168x48.svg","contentUrl":"https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/12/07162335/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https://www.ipsen.com/#/schema/logo/image/"},"sameAs":["https://www.facebook.com/Ipsengroup","https://x.com/ipsengroup"]},{"@type":"Person","@id":"https://www.ipsen.com/#/schema/person/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://www.ipsen.com/#/schema/person/image/","url":"https://secure.gravatar.com/avatar/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https://secure.gravatar.com/avatar/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https://www.ipsen.com"]}]}</script>  <link rel='dns-prefetch' href='//maps.google.com' /> <style id='wp-emoji-styles-inline-css'> img.wp-smiley, img.emoji { display: inline !important; border: none !important; box-shadow: none !important; height: 1em !important; width: 1em !important; margin: 0 0.07em !important; vertical-align: -0.1em !important; background: none !important; padding: 0 !important; } </style> <link rel='stylesheet' id='wp-block-library-css' href='https://www.ipsen.com/wp-includes/css/dist/block-library/style.min.css?ver=6.7.2' media='all' /> <style id='wp-block-library-theme-inline-css'> .wp-block-audio :where(figcaption){color:#555;font-size:13px;text-align:center}.is-dark-theme .wp-block-audio :where(figcaption){color:#ffffffa6}.wp-block-audio{margin:0 0 1em}.wp-block-code{border:1px solid #ccc;border-radius:4px;font-family:Menlo,Consolas,monaco,monospace;padding:.8em 1em}.wp-block-embed :where(figcaption){color:#555;font-size:13px;text-align:center}.is-dark-theme .wp-block-embed :where(figcaption){color:#ffffffa6}.wp-block-embed{margin:0 0 1em}.blocks-gallery-caption{color:#555;font-size:13px;text-align:center}.is-dark-theme .blocks-gallery-caption{color:#ffffffa6}:root :where(.wp-block-image figcaption){color:#555;font-size:13px;text-align:center}.is-dark-theme :root :where(.wp-block-image figcaption){color:#ffffffa6}.wp-block-image{margin:0 0 1em}.wp-block-pullquote{border-bottom:4px solid;border-top:4px solid;color:currentColor;margin-bottom:1.75em}.wp-block-pullquote cite,.wp-block-pullquote footer,.wp-block-pullquote__citation{color:currentColor;font-size:.8125em;font-style:normal;text-transform:uppercase}.wp-block-quote{border-left:.25em solid;margin:0 0 1.75em;padding-left:1em}.wp-block-quote cite,.wp-block-quote footer{color:currentColor;font-size:.8125em;font-style:normal;position:relative}.wp-block-quote:where(.has-text-align-right){border-left:none;border-right:.25em solid;padding-left:0;padding-right:1em}.wp-block-quote:where(.has-text-align-center){border:none;padding-left:0}.wp-block-quote.is-large,.wp-block-quote.is-style-large,.wp-block-quote:where(.is-style-plain){border:none}.wp-block-search .wp-block-search__label{font-weight:700}.wp-block-search__button{border:1px solid #ccc;padding:.375em .625em}:where(.wp-block-group.has-background){padding:1.25em 2.375em}.wp-block-separator.has-css-opacity{opacity:.4}.wp-block-separator{border:none;border-bottom:2px solid;margin-left:auto;margin-right:auto}.wp-block-separator.has-alpha-channel-opacity{opacity:1}.wp-block-separator:not(.is-style-wide):not(.is-style-dots){width:100px}.wp-block-separator.has-background:not(.is-style-dots){border-bottom:none;height:1px}.wp-block-separator.has-background:not(.is-style-wide):not(.is-style-dots){height:2px}.wp-block-table{margin:0 0 1em}.wp-block-table td,.wp-block-table th{word-break:normal}.wp-block-table :where(figcaption){color:#555;font-size:13px;text-align:center}.is-dark-theme .wp-block-table :where(figcaption){color:#ffffffa6}.wp-block-video :where(figcaption){color:#555;font-size:13px;text-align:center}.is-dark-theme .wp-block-video :where(figcaption){color:#ffffffa6}.wp-block-video{margin:0 0 1em}:root :where(.wp-block-template-part.has-background){margin-bottom:0;margin-top:0;padding:1.25em 2.375em} </style> <style id='classic-theme-styles-inline-css'> /*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} </style> <style id='global-styles-inline-css'> :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} </style> <link data-minify="1" rel='stylesheet' id='wpml-blocks-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/plugins/sitepress-multilingual-cms/dist/css/blocks/styles.css?ver=1739443667' media='all' /> <link data-minify="1" rel='stylesheet' id='wpgmp-frontend-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/plugins/wp-google-map-gold/assets/css/frontend.min.css?ver=1739443667' media='all' /> <link rel='stylesheet' id='bootstrap-min-css' href='https://www.ipsen.com/wp-content/themes/ipsen-main/dist/css/bootstrap.min.css?ver=1739806752' media='all' /> <link rel='stylesheet' id='caraousal-glider-min-css' href='https://www.ipsen.com/wp-content/themes/ipsen-main/dist/css/glider.min.css?ver=1739806752' media='all' /> <link data-minify="1" rel='stylesheet' id='slick-theme-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/css/slick-theme.css?ver=1739443667' media='all' /> <link data-minify="1" rel='stylesheet' id='slick-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/css/slick.css?ver=1739443667' media='all' /> <link data-minify="1" rel='stylesheet' id='media-filter-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/css/media-filter.css?ver=1739443667' media='all' /> <link data-minify="1" rel='stylesheet' id='ipsen-gravity-form-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/css/gravity-form-style.css?ver=1739443667' media='all' /> <link data-minify="1" rel='stylesheet' id='single-post-css-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/css/single-post.css?ver=1739443667' media='all' /> <link data-minify="1" rel='stylesheet' id='related-story-css-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/css/related-story.css?ver=1739443667' media='all' /> <link data-minify="1" rel='stylesheet' id='global-css-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/css/global.css?ver=1739443667' media='all' /> <link data-minify="1" rel='stylesheet' id='ipsenmain-style-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/style.css?ver=1739443667' media='all' /> <link data-minify="1" rel='stylesheet' id='book-meeting-css' href='https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/template-parts/ipsen-blocks/book-meeting/css/book-meeting.css?ver=1739443667' media='all' /> <script id="wpml-cookie-js-extra"> var wpml_cookies = {"wp-wpml_current_language":{"value":"en","expires":1,"path":"\/"}}; var wpml_cookies = {"wp-wpml_current_language":{"value":"en","expires":1,"path":"\/"}}; </script> <script data-minify="1" src="https://www.ipsen.com/wp-content/cache/min/0/wp-content/plugins/sitepress-multilingual-cms/res/js/cookies/language-cookie.js?ver=1739443667" id="wpml-cookie-js" defer data-wp-strategy="defer"></script> <script src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/js/jquery.min.js?ver=1739806752" id="jquery-min-theme-js"></script> <script src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/js/bootstrap.min.js?ver=1739806752" id="bootstrap-min-js"></script> <script src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/js/popper.min.js?ver=1739806752" id="popper-min-js"></script> <script src="https://www.ipsen.com/wp-includes/js/jquery/jquery.min.js?ver=3.7.1" id="jquery-core-js"></script> <script src="https://www.ipsen.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.4.1" id="jquery-migrate-js"></script> <script data-minify="1" src="https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/js/jquery.overflowing.js?ver=1739443667" id="jquery-overflowing-js"></script> <link rel="https://api.w.org/" href="https://www.ipsen.com/wp-json/" /><link rel="alternate" title="JSON" type="application/json" href="https://www.ipsen.com/wp-json/wp/v2/press_release/71425" /><link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://www.ipsen.com/xmlrpc.php?rsd" /> <meta name="generator" content="WordPress 6.7.2" /> <link rel='shortlink' href='https://www.ipsen.com/?p=71425' /> <link rel="alternate" title="oEmbed (JSON)" type="application/json+oembed" href="https://www.ipsen.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.ipsen.com%2Fpress-releases%2Fbylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434%2F" /> <link rel="alternate" title="oEmbed (XML)" type="text/xml+oembed" href="https://www.ipsen.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.ipsen.com%2Fpress-releases%2Fbylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434%2F&format=xml" /> <meta name="generator" content="WPML ver:4.6.9 stt:1,4;" /> <input type="hidden" id="ipn-all-sites" value="["us","annualreport","mx","aus","germany","be","netherlands","it","greece","japan","austria","switzerland","cn","france","canada","spain","uae-gulf","uk","nordics","kr","br"]"><link rel="icon" href="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19135239/favicon.png" sizes="32x32" /> <link rel="icon" href="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19135239/favicon.png" sizes="192x192" /> <link rel="apple-touch-icon" href="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19135239/favicon.png" /> <meta name="msapplication-TileImage" content="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19135239/favicon.png" /> <noscript><style id="rocket-lazyload-nojs-css">.rll-youtube-player, [data-lazy-src]{display:none !important;}</style></noscript>  <script type="text/javascript" src="https://cdn.cookielaw.org/consent/d11c622a-1c38-4917-b40c-dbf9215c59e9/OtAutoBlock.js" ></script> <script src=https://cdn.cookielaw.org/scripttemplates/otSDKStub.js type="text/javascript" charset="UTF-8" data-domain-script="d11c622a-1c38-4917-b40c-dbf9215c59e9" ></script> <script type="text/javascript"> function OptanonWrapper() { } </script>  </head> <body class="press_release-template-default single single-press_release postid-71425 wp-custom-logo no-js singular has-main-navigation"> <script> (function(window,document,dataLayerName,id){ window[dataLayerName]=window[dataLayerName]||[],window[dataLayerName].push({start:(new Date).getTime(),event:"stg.start"});var scripts=document.getElementsByTagName('script')[0],tags=document.createElement('script'); function stgCreateCookie(a,b,c){var d="";if(c){var e=new Date;e.setTime(e.getTime()+24*c*60*60*1e3),d=";expires="+e.toUTCString()}document.cookie=a+"="+b+d+";path=/"} var isStgDebug=(window.location.href.match("stg_debug")||document.cookie.match("stg_debug"))&&!window.location.href.match("stg_disable_debug");stgCreateCookie("stg_debug",isStgDebug?1:"",isStgDebug?14:-1); var qP=[];dataLayerName!=="dataLayer"&&qP.push("data_layer_name="+dataLayerName),isStgDebug&&qP.push("stg_debug");var qPString=qP.length>0?("?"+qP.join("&")):""; tags.async=!0,tags.src="https://myipsen.containers.piwik.pro/"+id+".js"+qPString,scripts.parentNode.insertBefore(tags,scripts); !function(a,n,i){a[n]=a[n]||{};for(var c=0;c<i.length;c++)!function(i){a[n][i]=a[n][i]||{},a[n][i].api=a[n][i].api||function(){var a=[].slice.call(arguments,0);"string"==typeof a[0]&&window[dataLayerName].push({event:n+"."+i+":"+a[0],parameters:[].slice.call(arguments,1)})}}(i[c])}(window,"ppms",["tm","cm"]); })(window,document,'dataLayer','bc936ea2-3363-4e59-ae1d-225c5bacf308'); </script> <div class="container-fluid siteId-1"> <div class="skiptocontent-box hidden-xs hidden-sm">  <a id="skipToMainContent" href="#main" class="sr-only skipToContent">Skip to main content</a> </div>  <section class="masthead sticky-top" id="masthead"> <div class="container"> <div class="row"> <nav class="navbar navbar-expand-lg navbar-light"> <div class="col-lg-4 col-md-12 col-sm-12 mobHeadView"> <a class="navbar-brand" href="https://www.ipsen.com/" aria-label="Ipsen Home Page"> <span class="custom-logo-link"> <img fetchpriority="high" src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/12/07162335/Latest_Ipsen-logo_168x48.svg" class="custom-logo" alt="Ipsen Home Page" decoding="async"> </span> </a> <a class="nav-link mobile-view searchDropdown" aria-current="page" id="searchDropdownLnk" href="#" aria-label="Search" aria-labelledby="searchDropdown" role="button" title="Search" data-bs-toggle="dropdown" data-bs-auto-close="outside" aria-expanded="false"></a> <div class="dropdown-menu searchBar dropdown-menu-end" aria-labelledby="searchDropdown" id="searchDropdownMobile" data-bs-auto-close="false"> <div class="row"> <div class="col-sm-3 col-md-3"> <select class="form-select shadow-none" aria-label="Default-select" name="cat" id="category_list" onChange="getCategory(this.value)" > <option selected value=""> All </option> <option value="post">Stories</option> <option value="press_release">Press Releases</option> <option value="attachment">Documents</option> <option value="event">Events</option> <option value="statements">Statements</option> <option value="others">Other</option> </select> </div> <input class="form-control" type="hidden" value="1" name="currentstore" id="currentstore"/> <input class="form-control" type="hidden" value="en" name="current_language_code_piped" id="current_language_code_piped"/> <input class="form-control" type="hidden" value="Global" name="current_blog_name" id="current_blog_name"/> <div class="col-sm-9 col-md-9"> <div class="input-group" id="inputInfo"> <input class="form-control shadow-none searchInput" type="search" value="" name="s" onKeyUp="show_results(this.value)" onChange="show_results(this.value)" autofocus/> <span class="input-group-append"> <button class="btn bg-white" type="button" aria-label="Search-button" onClick="send_search_data(this)" > <span class="search-right-arrow"></span> </button> </span> </div> </div> </div> <hr class="hr-search-divider"> <div class="row"> <div class="lds-dual-ring overlay loader" style="display:none;"> Loading...</div> <div class="cacheList autoSuggestion"> </div> </div> </div> <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarSupportedGlobal" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> </div> <div class="col-md-12 col-sm-12"> <div class="collapse navbar-collapse" id="navbarSupportedGlobal"> <ul class="nav navbar ms-auto mb-2 mb-lg-0 navbar-expand-lg globalNavigation"> <li class="nav-item dropdown"> </li> <li class="nav-item dropdown has-megamenu"> <a href="#" class="nav-link cool-link" id="megaDropdown" role="button" data-bs-toggle="dropdown" data-bs-auto-close="outside" aria-expanded="false">Media  <img src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/down.png" alt=""></a> <div class="dropdown-menu megamenu" aria-labelledby="megaDropdown"> <div class="row"> <div class="col-lg-6 col-md-6 col-sm-6 megamenu-left"> <div class="col-megamenu"> <a href="#" class="go-back-menu mobile-view" aria-label="Back to main navigation menu"> < Back </a> <ul class="list-unstyled submenu" aria-labelledby="megaDropdown"> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/press-release/">Press Releases </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/media-statements/">Media Statements </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/media-library/">Media Library </a> </li> </ul> </div> </div> <div class="col-lg-6 col-md-6 col-sm-6 megamenu-right"> <div class="col-megamenu"> <ul class="list-unstyled submenu"> <li> <div class="megamenuFeature"> <a href="https://www.ipsen.com/general/our-2023-integrated-annual-report-is-live/"><p>Our 2023 Integrated Annual Report is live!</p></a> <img class="img-fluid" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20260%20140'%3E%3C/svg%3E" width="260px" height="140px" alt="Featured Image" title="Featured Image" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/05/17174619/TL-graphic.jpg" ><noscript><img class="img-fluid" src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/05/17174619/TL-graphic.jpg" width="260px" height="140px" alt="Featured Image" title="Featured Image" ></noscript> </div> </li> </ul> </div> </div> </div> </div> </li> <li class="nav-item dropdown"> <a href="#" class="nav-link cool-link" role="button" data-bs-toggle="dropdown" data-bs-auto-close="outside" aria-expanded="false">Investors <img src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/down.png" alt=""> </a> <ul class="dropdown-menu submenu" aria-labelledby="navbarDropdown"> <a href="#" class="go-back-menu mobile-view" aria-label="Back to main navigation menu"> < Back </a> <li> <a class="nav-link cool-link active mobile-view">Investors</a></li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/investors/">Investors </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/investors/financial-results/">Financial Results </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/investors/reports-and-accounts/">Annual Reports and Accounts </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/investors/corporate-news/">Corporate News </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/investors/financial-calendar/">Financial Calendar </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/investors/investor-events/">Investor Events </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/investors/shareholders-information/">Shareholder Information </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/investors/regulated-information/">Regulated Information </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/contact-us/key-contacts/">Key Contacts </a> </li> </ul> <li class="nav-item "> <a class="nav-link cool-link " href="https://www.ipsen.com/partnering/" target="_self" >Partnering</a> </li> <li class="nav-item dropdown"> <a href="#" class="nav-link cool-link" role="button" data-bs-toggle="dropdown" data-bs-auto-close="outside" aria-expanded="false">Careers <img src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/down.png" alt=""> </a> <ul class="dropdown-menu submenu" aria-labelledby="navbarDropdown"> <a href="#" class="go-back-menu mobile-view" aria-label="Back to main navigation menu"> < Back </a> <li> <a class="nav-link cool-link active mobile-view">Careers</a></li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/careers/">Careers </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/careers/working-at-ipsen/">Working at Ipsen </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/careers/our-culture/">Culture </a> </li> </ul> </ul> <div class="vr verticle-divider"></div> <ul class="nav navbar navbar-expand-lg globalRight"> <li class="nav-item dropdown"> <a class="nav-link desktop-view searchDropdown" aria-current="page" id="searchDropdownMnu" href="#" aria-label="Search" role="button" title="Search" data-bs-toggle="dropdown" data-bs-auto-close="outside" aria-expanded="false"></a> <div class="dropdown-menu searchBar dropdown-menu-end" aria-labelledby="searchDropdown" id="searchDropdownMnu" data-bs-auto-close="false"> <div class="row"> <div class="col-sm-3 col-md-3 searchDivider search-left-grid"> <select class="form-select shadow-none" aria-label="Default-select" name="cat" id="cat_list" onChange="getCategory(this.value)"> <option value="">All</option> <option value="post">Stories</option> <option value="press_release">Press Releases</option> <option value="attachment">Documents</option> <option value="event">Events</option> <option value="statements">Statements</option> <option value="others">Other</option> </select> </div> <div class="col-sm-9 col-md-9 search-right-grid"> <div class="input-group" id="inputInfo"> <input class="form-control" type="hidden" value="1" name="currentstore" id="currentstore"/> <input class="form-control" type="hidden" value="Global" name="current_blog_name" id="current_blog_name"/> <input type="hidden" value="" name="cat" id="cat" /> <input class="form-control shadow-none searchInput" type="search" value="" name="s" onKeyUp="show_results(this.value)" onChange="show_results(this.value)" autofocus style="width:80%;"/> <span class="input-group-append"> <button class="btn bg-white" type="button" onClick="send_search_data(this)"> <span class="search-right-arrow"></span> </button> </span> </div> </div> </div> <hr class="hr-search-divider"> <div class="row"> <div class="lds-dual-ring overlay loader" style="display:none;"> Loading...</div> <div class="cacheList autoSuggestion"> </div> </div> </div> </li> <li class="nav-item dropdown lang-dropdown"> <a class="nav-link active languageDropdown mobile-view" href="https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/" aria-label="English" >English&emsp; EN</a> &emsp;&emsp;&emsp; <a class="nav-link languageDropdown mobile-view" href="https://www.ipsen.com/fr/press-releases/bylvay-odevixibat-montre-une-amelioration-soutenue-en-termes-de-severite-des-demangeaisons-et-de-taux-dacides-biliaires-seriques-chez-les-patients-atteints-de-cifp-et-du-sag-2982434/" aria-label="Français" >Français&emsp; FR</a> &emsp;&emsp;&emsp; <a class="nav-link desktop-view" href="#" id="languageDropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false" aria-label="Language-dropdown" >EN  <img src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/down.png" alt="arrow_down" title="arrow_down" ></a> <ul class="dropdown-menu langUl dropdown-menu-end" aria-labelledby="navbarDropdown"> <li> <a lang="EN" class="dropdown-item language active" href="https://www.ipsen.com/press-releases/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434/" aria-label="English" > English <span>EN</span> </a> </li> <li> <a lang="FR" class="dropdown-item language " href="https://www.ipsen.com/fr/press-releases/bylvay-odevixibat-montre-une-amelioration-soutenue-en-termes-de-severite-des-demangeaisons-et-de-taux-dacides-biliaires-seriques-chez-les-patients-atteints-de-cifp-et-du-sag-2982434/" aria-label="Français" > Français <span>FR</span> </a> </li> </ul> </li> <li class="nav-item dropdown"> <form> <a class="nav-link" href="#" id="globalDropdown" data-bs-auto-close="outside" data-bs-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false" aria-label="Change country or language"><img src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/Global.png" alt="Global" title="Global" > Global</a> <div class="dropdown-menu globalUl dropdown-menu-end" aria-labelledby="globalDropdown"> <div class="container globalUlContainer"> <a aria-label="Back to main navigation menu" class="nav-link globalDropdown go-country-back mobile-view" href="#" id="globalDropdownMobile"> < Back </a> <ul class="default_cnty"> <li><a class="active" href="https://www.ipsen.com">Global</a> <a class="globalDropdown active" aria-label="English" href="https://www.ipsen.com/"> EN</a> <a class="globalDropdown " aria-label="Français" href="https://www.ipsen.com/fr"> FR</a> </li> <li><a href="https://www.ipsen.com/annualreport" class="">Annual Report</a> <a href="https://www.ipsen.com/annualreport" class="globalDropdown " aria-label="English" >EN</a> <a href="https://www.ipsen.com/annualreport/fr" class="globalDropdown " aria-label="Français" >FR</a> </li> </ul> <ul class="nav nav-tabs globalTab" id="globalTab" role="tablist"> <li class="nav-item" role="presentation"> <a href="#pane0" class="nav-link active " id="pane-0" data-bs-toggle="tab" data-bs-target="#pane0" role="tab" aria-controls="pane0" aria-label="Americas">Americas</a> </li> <li class="nav-item" role="presentation"> <a href="#pane1" class="nav-link " id="pane-1" data-bs-toggle="tab" data-bs-target="#pane1" role="tab" aria-controls="pane1" aria-label="Asia Pacific">Asia Pacific</a> </li> <li class="nav-item" role="presentation"> <a href="#pane2" class="nav-link " id="pane-2" data-bs-toggle="tab" data-bs-target="#pane2" role="tab" aria-controls="pane2" aria-label="Europe">Europe</a> </li> </ul> <div class="tab-content" id="myTabContent"> <div class="tab-pane fade show active " id="pane0" role="tabpanel" aria-labelledby="pane-0"> <ul class="americas"> <li><a href="https://www.ipsen.com/us/" target="_blank">United States</a> </li> <li><a href="https://www.ipsen.com/brazil/" target="_blank">Brazil</a> </li> <li><a href="https://www.ipsen.com/canada/" target="_blank">Canada</a> </li> <li><a href="https://www.ipsen.com/mx/" target="_blank">Mexico</a> </li> </ul> </div> <div class="tab-pane fade show " id="pane1" role="tabpanel" aria-labelledby="pane-1"> <ul class="asia-pacific"> <li><a href="https://www.ipsen.com/aus/" target="_blank">Australia</a> </li> <li><a href="https://www.ipsen.com/cn/" target="_blank">China</a> </li> <li><a href="https://www.ipsen.com/singapore/" target="_blank">Singapore</a> </li> <li><a href="https://www.ipsen.com/korea/" target="_blank">South Korea</a> </li> <li><a href="https://www.ipsen.com/japan/" target="_blank">Japan</a> </li> </ul> </div> <div class="tab-pane fade show " id="pane2" role="tabpanel" aria-labelledby="pane-2"> <ul class="europe"> <li><a href="https://www.ipsen.com/be/" target="_blank">Belgium</a> </li> <li><a href="https://www.ipsen.com/ukraine/" target="_blank">Ukraine</a> </li> <li><a href="https://www.ipsen.com/uk-ireland/" target="_blank">UK</a> </li> <li><a href="https://www.ipsen.com/germany/" target="_blank">Germany</a> </li> <li><a href="https://www.ipsen.com/france/" target="_blank">France</a> </li> <li><a href="https://www.ipsennordic.com/" target="_blank">Nordics</a> </li> <li><a href="https://www.ipsen.com/greece/" target="_blank">Greece</a> </li> <li><a href="https://www.ipsen.com/it/" target="_blank">Italy</a> </li> <li><a href="https://www.ipsen.com/netherlands/" target="_blank">Netherlands</a> </li> <li><a href="https://www.ipsen.com/spain/" target="_blank">Spain</a> </li> <li><a href="https://www.ipsen.com/poland/" target="_blank">Poland</a> </li> <li><a href="https://www.ipsen.com/russia/" target="_blank">Russia</a> </li> <li><a href="https://www.ipsen.com/czc/" target="_blank">Czech Republic</a> </li> <li><a href="https://www.ipsen.com/switzerland/" target="_blank">Switzerland</a> </li> </ul> </div> </div> </div> </div> </form> </li> </ul> <div class="col-md-12 col-sm-12"> <ul class="navbar-nav"> <li class="nav-item "> <a class="nav-link cool-link " target="_self" href="https://www.ipsen.com/">Home</a> </li> <li class="nav-item dropdown"> <a href="#" class="nav-link cool-link" role="button" data-bs-toggle="dropdown" data-bs-auto-close="outside" aria-expanded="false">Company<img src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/down.png" alt=""></a> <ul class="dropdown-menu submenu" aria-labelledby="navbarDropdown"> <a href="#" class="go-back-menu mobile-view" aria-label="Back to main navigation menu"> < Back </a> <li> <a class="nav-link cool-link active mobile-view">Company</a></li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/company/">Company </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/company/leadership-team/">Leadership </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/company/history/">History </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/company/foundation-ipsen/">Fondation Ipsen </a> </li> </ul> <li class="nav-item dropdown"> <a href="#" class="nav-link cool-link" role="button" data-bs-toggle="dropdown" data-bs-auto-close="outside" aria-expanded="false">Science<img src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/down.png" alt=""></a> <ul class="dropdown-menu submenu" aria-labelledby="navbarDropdown"> <a href="#" class="go-back-menu mobile-view" aria-label="Back to main navigation menu"> < Back </a> <li> <a class="nav-link cool-link active mobile-view">Science</a></li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/oncology/">Oncology </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/rare-diseases/">Rare Disease </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/neuroscience/">Neuroscience </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/our-products/">Products </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/research-and-development/">R&D </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/pipeline/">Pipeline </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/clinical-trials/">Clinical Trials </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/lay-summaries/">Lay Summaries </a> </li> </ul> <li class="nav-item dropdown"> <a href="#" class="nav-link cool-link" role="button" data-bs-toggle="dropdown" data-bs-auto-close="outside" aria-expanded="false">Sustainability<img src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/down.png" alt=""></a> <ul class="dropdown-menu submenu" aria-labelledby="navbarDropdown"> <a href="#" class="go-back-menu mobile-view" aria-label="Back to main navigation menu"> < Back </a> <li> <a class="nav-link cool-link active mobile-view">Sustainability</a></li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/sustainability/">Sustainability </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/sustainability/environment/">Environment </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/sustainability/patients/">Patients </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/sustainability/people/">People </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/sustainability/governance/">Governance </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/sustainability/our-standards/">Our Standards </a> </li> </ul> <li class="nav-item dropdown"> <a href="#" class="nav-link cool-link" role="button" data-bs-toggle="dropdown" data-bs-auto-close="outside" aria-expanded="false">Patients<img src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/down.png" alt=""></a> <ul class="dropdown-menu submenu" aria-labelledby="navbarDropdown"> <a href="#" class="go-back-menu mobile-view" aria-label="Back to main navigation menu"> < Back </a> <li> <a class="nav-link cool-link active mobile-view">Patients</a></li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/patients/">Patients </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/patients/together-for-oncology/">Together for Oncology </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/patients/together-for-rare-disease/">Together for Rare Disease </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/patients/together-for-neuroscience/">Together for Neuroscience </a> </li> <li><a class="dropdown-item submenu-item" href="https://www.ipsen.com/patients/collaborate-with-us/">Collaborate with us </a> </li> </ul> <li class="nav-item "> <a class="nav-link cool-link " target="_self" href="https://www.ipsen.com/stories/">Stories</a> </li> </ul> </div> </div> </div> </nav>  </div> </div> </section>   <div class="page-template single-post-template class="post-71425 press_release type-press_release status-publish hentry category-corporate-pressrelease category-rare-diseases-pressrelease entry"" id="post-71425"> <div class="main-container" role="main" id="main">   <div class="container"> <div class="page-navigation"> <div class="page-back"> <a href="https://www.ipsen.com/"><span class="back-button">Back</span></a> </div> <div class="next-prev-sect"> <nav class="navigation post-navigation" aria-label="Posts"> <h2 class="screen-reader-text">Post navigation</h2> <div class="nav-links"><div class="nav-previous"><a href="https://www.ipsen.com/press-releases/iqirvo-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-with-improvements-in-fatigue-and-pruritus-2982128/" rel="prev"><span class="prev-button">Previous</span></a></div><div class="nav-next"><a href="https://www.ipsen.com/press-releases/ipsen-and-biomunex-announce-exclusive-global-licensing-agreement-for-first-in-class-mait-cell-engager-in-immuno-oncology-2990251/" rel="next"><span class="next-button">Next</span></a></div></div> </nav> </div> </div> <div class="row" id="downloadPdf" data-title="Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS" > <div class="generate-pdf hidden">  <h3 class="page-head">Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS</h3> <div class="content_area"> <ul type="disc"> <li style="margin-top:6pt;text-align:left"><strong><em>Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024</em></strong></li> </ul> <p align="justify"><strong>PARIS, FRANCE, 18 November, 2024 </strong>Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay<sup><strong><em>®</em></strong></sup> from two Phase III open-label extension studies: late-breaking abstract (#5045) on PEDFIC 2 in Progressive Familial Intrahepatic Cholestasis (PFIC) and oral presentation ASSERT-EXT (#50) in Alagille syndrome (ALGS). Sustained efficacy data and improvements in height, weight and sleep measures were observed for patients treated with Bylvay for at least 72 weeks in both rare cholestatic diseases.</p> <p align="justify">“We know from our work with patient communities that receiving a diagnosis of PFIC and ALGS can be overwhelming in a patient or caregivers’ life. Disease symptoms like severe itch can have an impact on the whole family,” said Sandra Silvestri, EVP Chief Medical Officer, Ipsen. “Data suggesting Bylvay-treated patients experienced sustained efficacy, and which support the safety and tolerability profile seen in previous clinical trials, are important. Ipsen is committed to being the leader across rare cholestatic liver diseases and we are just getting started.”</p> <p><strong><em>PEDFIC 2 Study in PFIC</em></strong></p> <p align="justify">“These open-label extension data from PEDFIC 2 suggest that the initial reduction in pruritus and in serum bile acid levels achieved following initiation of odevixibat are being sustained into the longer term,” said Dr. Richard J. Thompson, Professor of Molecular Hepatology, King’s College London and principal investigator of the PEDFIC 2 trial. “We are also observing reductions in both pruritus and serum bile acid across a number of PFIC subtypes. This is important information for our understanding of the therapeutic management of our patients living with PFIC.” </p> <p align="justify">PEDFIC 2 was an open-label extension study (n=116; patients from PEDFIC 1 Bylvay and placebo cohorts at week 24, and new Bylvay-naïve patients of any age and PFIC subtype), evaluating the efficacy and safety of Bylvay through 72 weeks (n=83).<sup><strong><em>1</em></strong></sup> The data showed a clinically meaningful 1-point reduction in pruritus score at week 72 in 42 percent of patients <18 years old with PFIC 1 and 2 who transitioned to Bylvay at 24 weeks (n=5/12) and 61 percent of patients with any type of PFIC and of any age excluding episodic (n=19/31). Rapid initial pruritus scores achieved by week 4 were sustained for patients who remained on treatment. At 72 weeks, the mean change in serum bile acid (sBA) levels from patients who transition to Bylvay at week 24 (n=15) was –104.00 µmol/L and Bylvay-treated patients (n=43) was -57.97 µmol/L . </p> <p align="justify">Beyond the clinically meaningful and sustained improvements seen in pruritus and sBA levels, height, weight and sleep increases were reported at 72 weeks in Bylvay-treated patients. Most adverse events in Bylvay-treated patients over the duration of the study were reported as mild or moderate. The most common were gastrointestinal (17.2 percent; n=20/116), including diarrhea (12 percent; n=14/116). In two cases, diarrhea led to one treatment interruption and one discontinuation.</p> <p align="justify"><strong><em>Assert-EXT Study in ALGS</em></strong><br />“The sustained improvements we’ve seen in Bylvay-treated individuals living with Alagille syndrome are encouraging,” said Dr. Nadia Ovchinsky, Chief, Division of Gastroenterology and Hepatology, Hassenfeld Children’s Hospital at NYU Langone, New York. and principal investigator of the ASSERT trial. “These results not only show the potential to manage symptoms like pruritus, which can be extremely difficult for children and their parents to manage, but we’re also seeing a consistent safety profile over the longer term with sustained tolerability.”</p> <p align="justify">In ASSERT-EXT, the open-label extension study (n=50) evaluating the long-term efficacy and safety of Bylvay in ALGS patients (ages 1-15.9 years) through 72 weeks (n=44), sustained improvements were observed in pruritus and sBA levels through 72 weeks.<sup>2</sup> At week 72, 93 percent (n=28/30) of patients who received Bylvay throughout the 24 weeks ASSERT trial and 77 percent (n=10/13) of those who transitioned from placebo to Bylvay at week 24 experienced a clinically meaningful ≥1 point reduction in pruritus score. Reductions in sBA levels were also observed in patients treated with Bylvay for 72 weeks showing a mean reduction of 124 µmol/L in those who continuously received Bylvay and a mean reduction of 139 µmol/L in patients who transitioned from placebo to Bylvay. Mean changes from baseline were observed in height (8.2 cm) and weight (2.8 kg) on continuous Bylvay use and for patients who transitioned from placebo to Bylvay, height (10.7 cm) and weight (3.3 kg) mean changes were also reported. </p> <p>Improvements in sleep were observed from weeks 24 to 72 across all four sleep parameters (n=43), including proportion of days seeing blood due to scratching, proportion of days needing help falling asleep, proportion of days needing soothing and daytime tiredness. Data supports the safety profile in the ASSERT clinical trial for Bylvay. Treatment emergent adverse event (TEAE) occurred in 18 percent (n=6/33) of patients who continuously received Bylvay and 41 percent (n=7/17) of patients who transitioned from placebo to Bylvay. Most adverse events were mild or moderate with diarrhea as the most common TEAE. One TEAE led to discontinuation.</p> <p align="justify"><strong><em>About PFIC and ALGS</em></strong><br />PFIC is a group of rare genetic disorders in which bile acids build up in the liver, causing damage, which may result in liver failure. ALGS is also a rare genetic disorder, affecting multiple organs including the liver, heart, skeleton, eyes and kidneys. Without early diagnosis and effective management, people living with PFIC and ALGS may need a liver transplant. Debilitating itch, caused as a result of the serum bile acid build up, is one of the most common symptoms of both PFIC and ALGS, significantly impacting sleep and daily activities and resulting in skin mutilation, loss of sleep, irritability, and poor attention.</p> <p align="left"><strong><em>Bylvay (odevixibat) posters presented at AASLD</em></strong></p> <table style="border-collapse: collapse;width:460.7pt;border-collapse:collapse"> <tr> <td style="width:113.4px;text-align: left;vertical-align: middle;vertical-align: top"> <strong>Abstract</strong> </td> <td style="width:179.6px;text-align: left;vertical-align: middle;vertical-align: top"> <strong>Poster or Oral #</strong> </td> <td style="width:189px;text-align: left;vertical-align: middle;vertical-align: top"> <strong>Full title</strong> </td> <td style="width:132.27px;text-align: left;vertical-align: middle;vertical-align: top"> <strong>Authors </strong> </td> </tr> <tr> <td style="width:113.4px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top"> <strong>ASSERT-EXT </strong><br /><strong>final results</strong> </td> <td style="width:179.6px;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top;text-align: left;vertical-align: middle"> <em>Oral, Abstract Parallel, ePoster [50]</em><br /><strong>Monday 18 November </strong><br />11:45–12:00<br />Human Cholestatic, PBC and other Biliary Disorders in Children and Adults</p> <p> </p> <p> </td> <td style="width:189px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top"> ASSERT-EXT: Final data from an open-label, Phase 3 study of odevixibat in patients with Alagille syndrome </td> <td style="width:132.27px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top"> <strong>Nadia Ovchinsky et al.</strong> </td> </tr> <tr> <td style="width:113.4px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top"> <strong>Hepatic </strong><br /><strong>parameters with </strong><br /><strong>ODX in PFIC</strong> </td> <td style="width:179.6px;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top;text-align: left;vertical-align: middle"> <em>Poster, Abstract [4277]</em><br /><strong>Monday 18 November</strong><br />13:00–14:00<br />Poster Session IV </td> <td style="width:189px;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top;text-align: left;vertical-align: middle"> Effects of odevixibat vs placebo on hepatic biochemical parameters and liver adverse events in patients with PFIC: <br />Data from the PEDFIC 1 study</p> <p> </td> <td style="width:132.27px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top"> <strong>Tassos Grammatikopoulos et al. </strong> </td> </tr> <tr> <td style="width:113.4px;border-top: solid black 1pt;vertical-align: top"> </p> <p> </p> <p> <strong>Phase I </strong><br /><strong>DDI results</strong> </td> <td style="width:179.6px;border-top: solid black 1pt;vertical-align: top"> </p> <p> </p> <p> </p> <p> <em>Poster, Abstract [4280]</em><br /><strong>Monday 18 November</strong><br />13:00–14:00<br />Poster Session IV </td> <td style="width:189px;border-top: solid black 1pt;vertical-align: top"> </p> <p> </p> <p> A Phase 1, open-label, fixed-sequence, crossover study to evaluate the interaction of multiple-dose odevixibat with the pharmacokinetics of single-dose combined oral contraceptive steroids in healthy female participants</p> <p> </p> <p> </td> <td style="width:132.27px;border-top: solid black 1pt;vertical-align: top"> </p> <p> </p> <p> </p> <p> <strong>Florent Mazuir et al.</strong> </td> </tr> <tr> <td style="width:113.4px;border-bottom: solid black 1pt;vertical-align: top"> </td> <td style="width:179.6px;border-bottom: solid black 1pt;vertical-align: top"> </td> <td style="width:189px;border-bottom: solid black 1pt;vertical-align: top"> </td> <td style="width:132.27px;border-bottom: solid black 1pt;vertical-align: top"> </td> </tr> <tr> <td style="width:113.4px;text-align: left;vertical-align: middle;border-top: solid black 1pt;vertical-align: top"> <strong>PEDFIC1/2 OLE final results (LB)</strong> </td> <td style="width:179.6px;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;border-top: solid black 1pt;vertical-align: top;text-align: left;vertical-align: middle"> <em>Poster, Abstract [5045]</em><br /><strong>Monday 18 November</strong><br />13:00–14:00<br />Poster Session IV </td> <td style="width:189px;text-align: left;vertical-align: middle;border-top: solid black 1pt;vertical-align: top"> Sustained, long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: Results from the PEDFIC2 Phase 3, open-label extension study </td> <td style="width:132.27px;text-align: left;vertical-align: middle;border-top: solid black 1pt;vertical-align: top"> <strong>Richard Thompson et al.</strong> </td> </tr> </table> <p align="justify"><strong><em>About Bylvay (odevixibat)</em></strong><br />Odevixibat is a once-daily non-systemic ileal bile acid transport (IBAT) inhibitor approved under the brand name Bylvay<sup>®</sup> in the U.S. as the first drug treatment option for patients 3 months of age and older living with cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC). BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific <em>ABCB11 </em>variants resulting in non-functional or complete absence of the bile salt export pump protein.</p> <p align="justify">Odevixibat was also approved in June 2021 in the E.U. under the brand name Bylvay<sup>®</sup>, as the first drug treatment option for all types of PFIC in patients aged 6 months or older. Bylvay has received orphan exclusivity for the treatment of PFIC in the U.S. and E.U. </p> <p align="justify">In June 2023 Bylvay was approved in the U.S. for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome (ALGS) and received orphan exclusivity for ALGS. In September 2024, odevixibat was approved in the E.U under the brand name Kayfanda<sup>®</sup> for the treatment of cholestatic pruritus in ALGS in patients aged 6 months or older.</p> <p align="justify"><strong>IMPORTANT SAFETY INFORMATION – U.S.</strong><br /><strong>Warnings and Precautions:</strong></p> <p align="justify"><strong>Liver Test Abnormalities</strong><br />Patients who enrolled in PFIC and ALGS clinical trials had abnormal liver tests at baseline. In clinical trials, treatment-emergent elevations of liver tests or worsening of liver tests relative to baseline values were observed. Most abnormalities included elevations in aspartate aminotransferase (AST), alanine transaminase (ALT) in PFIC and ALGS, and total and direct bilirubin in PFIC clinical trials. No patients permanently discontinued treatment due to liver test abnormalities.</p> <p align="justify">Obtain baseline liver tests and monitor during treatment. Dose reduction or treatment interruption may be required if abnormalities occur. For persistent or recurrent liver test abnormalities, consider treatment discontinuation.</p> <p align="justify">Permanently discontinue Bylvay if a patient progresses to portal hypertension or experiences a hepatic decompensation event.</p> <p align="justify"><strong>Diarrhea</strong><br />Diarrhea occurred in both PFIC and ALGS clinical trials in BYLVAY-treated patients at a rate greater than placebo treated patients. If diarrhea occurs with use of BYLVAY, monitor for dehydration and treat promptly. Treatment interruption or discontinuation may be required for persistent diarrhea with no alternate etiology.</p> <p align="justify"><strong>Fat-Soluble Vitamin (FSV) Deficiency</strong><br />Fat-soluble vitamins (FSV) include vitamin A, D, E, and K. PFIC and ALGS patients can have FSV deficiency at baseline, as part of their disease. BYLVAY may affect absorption of fat-soluble vitamins.</p> <p align="justify">Obtain baseline levels and monitor during treatment, along with any clinical manifestations. Supplement if deficiency is observed. If FSV deficiency persists or worsens despite FSV supplementation, discontinue treatment.</p> <p align="justify"><strong>ADVERSE REACTIONS</strong><br /><strong>ALGS:</strong> The most common adverse reactions (>5%) are diarrhea, abdominal pain, hematoma, and decreased weight.<br /><strong>PFIC:</strong> The most common adverse reactions (>2%) are diarrhea, liver test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency.</p> <p align="justify"><strong>DRUG INTERACTIONS</strong><br />For patients taking bile acid binding resins, take BYLVAY at least 4 hours before or 4 hours after administering, as bile acid binding resins may bind to and reduce BYLVAY efficacy.</p> <p align="justify"><strong>USE IN SPECIFIC POPULATIONS</strong><br />There are no human data on BYLVAY use in pregnant persons to establish a drug-associated risk of major birth defects, miscarriage, or adverse developmental outcomes. Based on findings from animal reproduction studies, BYLVAY may cause cardiac malformations when a fetus is exposed during pregnancy.</p> <p align="justify">There is a pregnancy safety study that monitors pregnancy outcomes in women exposed to BYLVAY during pregnancy. Pregnant women exposed to BYLVAY, or their healthcare providers, should report BYLVAY exposure by calling 1-855-463-5127.</p> <p align="justify"><strong>To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at +1-855-463-5127, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</strong></p> <p align="justify"><strong>Indications and Usage U.S.</strong><br />Bylvay is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in:<br />Patients 12 months of age and older with Alagille syndrome (ALGS)<br />Patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC)</p> <p align="justify"><strong>Limitation of use</strong><br />Bylvay may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein</p> <p align="justify"><strong>Please see full U.S. </strong><a href="https://www.globenewswire.com/Tracker?data=-BsbTtxpWPxUWWlD-hpFl_hy33x0zMsNUH2etXPZPX7Y1CL6N8KOWH2JB6JwpKfjhWl57v4SRXox0FJMQ7n4MayF22w9si39XS9Ra8srTfaE2XwtwXdpebNbficfzhJlE3nSNze46jxE9GABLxrfgucdOtp1-83UdzXA-pIzonbnRWt1x1RkSFk4_fuo1Xm-o7nbIkHYgVKheZCXDL1iV1Ft-Y0zNCfgvBHtXD5lC34UchVcffeUpKOs3hrsxg51hOxbHJSJQtWqt-n40Pq-qhONTYQGuGXZUz4SprCjzUQ=" rel="nofollow noopener" target="_blank" title=""><strong>Prescribing Information</strong></a><strong>.</strong></p> <p align="left"><strong>Indications of use E.U.</strong><br />Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older. <strong>Please see full E.U.</strong><a href="https://www.globenewswire.com/Tracker?data=OvISGXdtHCmHru1d2jWPoEHr4EiFqHjNt1WIvtAKDa-pHjmelQGSfuilDw4N_McUGHwckAIf-x6AKc8uHHR3Zfupgq3JclN-53l7A8HxaH4y2L80YhHDb8NAX6J8zrilmrTp04AiKgpAsbEFiquQYWB4IWOf2oZSM6Fe4DtzJG0gAHF2Gir_pB941MO9YKP1ak-QiAayJAtVazWec6ZzQw==" rel="nofollow noopener" target="_blank" title=""><strong> Prescribing Information</strong></a><strong>.</strong></p> <p align="justify">Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older. <strong>Please see full E.U.</strong><a href="https://www.globenewswire.com/Tracker?data=OvISGXdtHCmHru1d2jWPoEHr4EiFqHjNt1WIvtAKDa-ZzkTxYrIrF3TGhy75Rn9e7wrOnnHd06uLUct-hZiylpB4it2tBf1ItqBvnTZEClbJEXRn0plGlwx9b--aL_j5cUFkZBakootIV9wIeJ-dLzfj5ufzEA_Zjmj7tIKhTK5_QcXUfQG3Q3yhuQesuRJMNXjIs_Pw7rvArr8iwiXJ0Q==" rel="nofollow noopener" target="_blank" title=""><strong> Prescribing Information.</strong></a></p> <p align="center"><strong>ENDS</strong></p> <p align="justify"><strong>About PEDFIC 1 and 2</strong><br />PEDFIC 1 was a 24-week double-blind, randomized, placebo-controlled trial that evaluated the efficacy and tolerability of two doses of odevixibat in reducing pruritus and serum bile acid levels in children with PFIC 1 or 2. PEDFIC 2 is a 72-week open label extension trial, which consisted of children from PEDFIC 1 who received either Bylvay (cohort 1a) or placebo (cohort 1b) and a new cohort (2) of Bylvay-naïve patients of any age and PFIC subtype. </p> <p align="justify">PEDFIC is the largest, global, Phase III trial ever conducted in PFIC. PEDFIC 1 (NCT03566238) was a 24-week double-blind, randomized (1:1:1), placebo-controlled trial that evaluated the efficacy and tolerability of two doses of odevixibat in reducing pruritus and serum bile acid levels in children with PFIC 1 or 2. Participants were randomly allocated to receive placebo (n=20), odevixibat 40 μg/kg (n=23), or odevixibat 120 μg/kg (n=19) once a day. The results were published in <em>The Lancet</em>.<sup>3</sup></p> <p align="justify">PEDFIC 2 (NCT03659916), an open-label extension of PEDFIC 1, is a 72-week trial that aimed to evaluate the efficacy and tolerability of odevixibat 120 µg/kg once a day in patients with PFIC. Patients were divided into two cohorts: Cohort 1 (n=56) which consisted of children with PFIC 1 or 2 from PEDFIC 1 who received odevixibat (Cohort 1a: n= 37) or placebo (Cohort 1b: n=19), respectively, and Cohort 2 (n=60) which consisted of newly enrolled, odevixibat-naïve patients of any age and PFIC subtype. Interim results were published in <em>The Journal of Hepatology</em>.<sup>4</sup></p> <p align="left"><strong>About ASSERT and ASSERT-EXT</strong><br />ASSERT (NCT04674761) was a 24-week double-blind, randomized, placebo-controlled trial with an open-label long term extension. ASSERT evaluated the safety and efficacy of 120 µg /kg once-daily odevixibat vs placebo for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The trial enrolled 52 patients of any age with a genetically confirmed diagnosis of ALGS. The results were published in <em>The Lancet</em>.<sup>5</sup></p> <p align="justify">In ASSERT-EXT (NCT05035030), ASSERT’s ongoing open-label extension, all trial participants received 120 μg/kg of odevixibat once daily for 72-weeks after the double-blind treatment period completed. In both ASSERT and ASSERT-EXT, the investigators looked for changes in pruritus, serum bile acid concentrations, sleep, and treatment-emergent adverse events.</p> <p align="left"><strong>About Ipsen</strong><br />We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. </p> <p align="justify">Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. </p> <p align="justify">Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com </p> <p align="left"><strong>Ipsen Media contacts </strong></p> <p align="justify"><strong>Investors</strong></p> <ul type="disc"> <li style="margin-bottom:6pt;text-align:justify"><strong>Nicolas Bogler | + 33 6 52 19 98 92 </strong></li> </ul> <p align="justify"><strong>Media</strong></p> <ul type="disc"> <li style="margin-bottom:6pt;text-align:justify"><strong>Jennifer Smith-Parker | + 44 7487 75 71 00 | jennifer.smith-parker.ext@ipsen.com</strong></li> <li style="margin-bottom:6pt;text-align:justify"><strong>Rachel Reiff | + 1 908 616 1680 | rachel.reiff@ipsen.com</strong></li> <li style="margin-bottom:6pt;text-align:justify"><strong>Anna Gibbins | + 44 7717 80 19 00 | anna.gibbins@ipsen.com</strong></li> </ul> <p align="left"><strong>Disclaimers and/or Forward-Looking Statements</strong></p> <p align="justify"><strong>Ipsen</strong> <br />The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.</p> <p align="left"><strong>References</strong></p> <p align="left"><sup>1</sup>Thompson RJ, et al. Sustained, long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: Results from the PEDFIC2 phase 3, open-label extension study. Poster Abstract 5045, American Association for the Study of Liver Disease (AASLD). 2024<br /><sup>2</sup> Ovchinsky N., et al. ASSERT-EXT: Final data from an open-label, phase 3 study of odevixibat in patients with Alagille syndrome. Oral abstract Parallel ePoster 50. American Association for the Study of Liver Disease (AASLD). 2024<br /><sup>3</sup> Thompson RJ, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022. 7:830–842.<br /><sup>4</sup> Thompson RJ, et al. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis 2023. JHEP Rep. 5(8):100782.<br /><sup>5</sup> Ovchinsky N., et al. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT); a phase 3, double-blind, randomized, placebo-controlled trial. Lancet Gastroenterol / Hepatol. 2024 doi.org/10.1016/S2468-1253(24)00074-8.</p> <p id="gnw_attachments_section-header"> <strong>Attachment</strong> </p> <ul id="gnw_attachments_section-items"> <li> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tbxEJcm1ZdVirmtaKPphAc6WlnR_gp1l9UmyE81UK2yoYfVvBAv-dAWKPFTuCKMOfqALSjUIsQxa47hkVkVqiTlKEH4EtX2RrM66WSJbtdyxAkboT-R-T4Zn_sFc20mO2JL5fk4JBsThlLzqYD31lWpSKe33PqLBsF6BXIoDQiMgoWsoviXZ13kUgo2ghIDUuJ5nkvzYIVP_GLi7ybdimIzbAVg0qTv19OSnNeIBxdT7hhmE_TK2OhtA-ucbGuNoREbLbn8P7jMckpJZWKd2cl6tFq-8qKTLw_tzgMcPb9o=" title="Ipsen PR_Bylvay® (odevixibat) data shows sustained improvement in severe itch and sBA in PFIC and ALGS_181124" rel="nofollow noopener">Ipsen PR_Bylvay® (odevixibat) data shows sustained improvement in severe itch and sBA in PFIC and ALGS_181124</a> </li> </ul> <p><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://ml-eu.globenewswire.com/media/YWMwMjE1MDctMmQxNC00MTU1LWI1MmMtZmMxYjllOGJiMmMzLTEyNjgxMTY=/tiny/Ipsen-Pharma.png" /><noscript><img alt="" src='https://ml-eu.globenewswire.com/media/YWMwMjE1MDctMmQxNC00MTU1LWI1MmMtZmMxYjllOGJiMmMzLTEyNjgxMTY=/tiny/Ipsen-Pharma.png' /></noscript></p> </div> </div> <div class="left-post-side column-1 col-xl-12 col-lg-12 col-md-12 col-sm-12"> <h3 class="page-head">Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS</h3> <div class="story-info-sec"> <button class="btn tag-btn green-btn" style="background-color:#224a81;"> Rare Diseases </button> <span class="desk-span"> - <span class="story-date">18 November 2024</span> - <span class="story-read-time">12 mins read</span></span> </div> <div class="page-filter-tags"> </div> <div class="content_area"> <ul type="disc"> <li style="margin-top:6pt;text-align:left"><strong><em>Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024</em></strong></li> </ul> <p align="justify"><strong>PARIS, FRANCE, 18 November, 2024 </strong>Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay<sup><strong><em>®</em></strong></sup> from two Phase III open-label extension studies: late-breaking abstract (#5045) on PEDFIC 2 in Progressive Familial Intrahepatic Cholestasis (PFIC) and oral presentation ASSERT-EXT (#50) in Alagille syndrome (ALGS). Sustained efficacy data and improvements in height, weight and sleep measures were observed for patients treated with Bylvay for at least 72 weeks in both rare cholestatic diseases.</p> <p align="justify">“We know from our work with patient communities that receiving a diagnosis of PFIC and ALGS can be overwhelming in a patient or caregivers’ life. Disease symptoms like severe itch can have an impact on the whole family,” said Sandra Silvestri, EVP Chief Medical Officer, Ipsen. “Data suggesting Bylvay-treated patients experienced sustained efficacy, and which support the safety and tolerability profile seen in previous clinical trials, are important. Ipsen is committed to being the leader across rare cholestatic liver diseases and we are just getting started.”</p> <p><strong><em>PEDFIC 2 Study in PFIC</em></strong></p> <p align="justify">“These open-label extension data from PEDFIC 2 suggest that the initial reduction in pruritus and in serum bile acid levels achieved following initiation of odevixibat are being sustained into the longer term,” said Dr. Richard J. Thompson, Professor of Molecular Hepatology, King’s College London and principal investigator of the PEDFIC 2 trial. “We are also observing reductions in both pruritus and serum bile acid across a number of PFIC subtypes. This is important information for our understanding of the therapeutic management of our patients living with PFIC.” </p> <p align="justify">PEDFIC 2 was an open-label extension study (n=116; patients from PEDFIC 1 Bylvay and placebo cohorts at week 24, and new Bylvay-naïve patients of any age and PFIC subtype), evaluating the efficacy and safety of Bylvay through 72 weeks (n=83).<sup><strong><em>1</em></strong></sup> The data showed a clinically meaningful 1-point reduction in pruritus score at week 72 in 42 percent of patients <18 years old with PFIC 1 and 2 who transitioned to Bylvay at 24 weeks (n=5/12) and 61 percent of patients with any type of PFIC and of any age excluding episodic (n=19/31). Rapid initial pruritus scores achieved by week 4 were sustained for patients who remained on treatment. At 72 weeks, the mean change in serum bile acid (sBA) levels from patients who transition to Bylvay at week 24 (n=15) was –104.00 µmol/L and Bylvay-treated patients (n=43) was -57.97 µmol/L . </p> <p align="justify">Beyond the clinically meaningful and sustained improvements seen in pruritus and sBA levels, height, weight and sleep increases were reported at 72 weeks in Bylvay-treated patients. Most adverse events in Bylvay-treated patients over the duration of the study were reported as mild or moderate. The most common were gastrointestinal (17.2 percent; n=20/116), including diarrhea (12 percent; n=14/116). In two cases, diarrhea led to one treatment interruption and one discontinuation.</p> <p align="justify"><strong><em>Assert-EXT Study in ALGS</em></strong><br />“The sustained improvements we’ve seen in Bylvay-treated individuals living with Alagille syndrome are encouraging,” said Dr. Nadia Ovchinsky, Chief, Division of Gastroenterology and Hepatology, Hassenfeld Children’s Hospital at NYU Langone, New York. and principal investigator of the ASSERT trial. “These results not only show the potential to manage symptoms like pruritus, which can be extremely difficult for children and their parents to manage, but we’re also seeing a consistent safety profile over the longer term with sustained tolerability.”</p> <p align="justify">In ASSERT-EXT, the open-label extension study (n=50) evaluating the long-term efficacy and safety of Bylvay in ALGS patients (ages 1-15.9 years) through 72 weeks (n=44), sustained improvements were observed in pruritus and sBA levels through 72 weeks.<sup>2</sup> At week 72, 93 percent (n=28/30) of patients who received Bylvay throughout the 24 weeks ASSERT trial and 77 percent (n=10/13) of those who transitioned from placebo to Bylvay at week 24 experienced a clinically meaningful ≥1 point reduction in pruritus score. Reductions in sBA levels were also observed in patients treated with Bylvay for 72 weeks showing a mean reduction of 124 µmol/L in those who continuously received Bylvay and a mean reduction of 139 µmol/L in patients who transitioned from placebo to Bylvay. Mean changes from baseline were observed in height (8.2 cm) and weight (2.8 kg) on continuous Bylvay use and for patients who transitioned from placebo to Bylvay, height (10.7 cm) and weight (3.3 kg) mean changes were also reported. </p> <p>Improvements in sleep were observed from weeks 24 to 72 across all four sleep parameters (n=43), including proportion of days seeing blood due to scratching, proportion of days needing help falling asleep, proportion of days needing soothing and daytime tiredness. Data supports the safety profile in the ASSERT clinical trial for Bylvay. Treatment emergent adverse event (TEAE) occurred in 18 percent (n=6/33) of patients who continuously received Bylvay and 41 percent (n=7/17) of patients who transitioned from placebo to Bylvay. Most adverse events were mild or moderate with diarrhea as the most common TEAE. One TEAE led to discontinuation.</p> <p align="justify"><strong><em>About PFIC and ALGS</em></strong><br />PFIC is a group of rare genetic disorders in which bile acids build up in the liver, causing damage, which may result in liver failure. ALGS is also a rare genetic disorder, affecting multiple organs including the liver, heart, skeleton, eyes and kidneys. Without early diagnosis and effective management, people living with PFIC and ALGS may need a liver transplant. Debilitating itch, caused as a result of the serum bile acid build up, is one of the most common symptoms of both PFIC and ALGS, significantly impacting sleep and daily activities and resulting in skin mutilation, loss of sleep, irritability, and poor attention.</p> <p align="left"><strong><em>Bylvay (odevixibat) posters presented at AASLD</em></strong></p> <table style="border-collapse: collapse;width:460.7pt;border-collapse:collapse"> <tr> <td style="width:113.4px;text-align: left;vertical-align: middle;vertical-align: top"> <strong>Abstract</strong> </td> <td style="width:179.6px;text-align: left;vertical-align: middle;vertical-align: top"> <strong>Poster or Oral #</strong> </td> <td style="width:189px;text-align: left;vertical-align: middle;vertical-align: top"> <strong>Full title</strong> </td> <td style="width:132.27px;text-align: left;vertical-align: middle;vertical-align: top"> <strong>Authors </strong> </td> </tr> <tr> <td style="width:113.4px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top"> <strong>ASSERT-EXT </strong><br /><strong>final results</strong> </td> <td style="width:179.6px;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top;text-align: left;vertical-align: middle"> <em>Oral, Abstract Parallel, ePoster [50]</em><br /><strong>Monday 18 November </strong><br />11:45–12:00<br />Human Cholestatic, PBC and other Biliary Disorders in Children and Adults</p> <p> </p> <p> </td> <td style="width:189px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top"> ASSERT-EXT: Final data from an open-label, Phase 3 study of odevixibat in patients with Alagille syndrome </td> <td style="width:132.27px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top"> <strong>Nadia Ovchinsky et al.</strong> </td> </tr> <tr> <td style="width:113.4px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top"> <strong>Hepatic </strong><br /><strong>parameters with </strong><br /><strong>ODX in PFIC</strong> </td> <td style="width:179.6px;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top;text-align: left;vertical-align: middle"> <em>Poster, Abstract [4277]</em><br /><strong>Monday 18 November</strong><br />13:00–14:00<br />Poster Session IV </td> <td style="width:189px;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top;text-align: left;vertical-align: middle"> Effects of odevixibat vs placebo on hepatic biochemical parameters and liver adverse events in patients with PFIC: <br />Data from the PEDFIC 1 study</p> <p> </td> <td style="width:132.27px;text-align: left;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top"> <strong>Tassos Grammatikopoulos et al. </strong> </td> </tr> <tr> <td style="width:113.4px;border-top: solid black 1pt;vertical-align: top"> </p> <p> </p> <p> <strong>Phase I </strong><br /><strong>DDI results</strong> </td> <td style="width:179.6px;border-top: solid black 1pt;vertical-align: top"> </p> <p> </p> <p> </p> <p> <em>Poster, Abstract [4280]</em><br /><strong>Monday 18 November</strong><br />13:00–14:00<br />Poster Session IV </td> <td style="width:189px;border-top: solid black 1pt;vertical-align: top"> </p> <p> </p> <p> A Phase 1, open-label, fixed-sequence, crossover study to evaluate the interaction of multiple-dose odevixibat with the pharmacokinetics of single-dose combined oral contraceptive steroids in healthy female participants</p> <p> </p> <p> </td> <td style="width:132.27px;border-top: solid black 1pt;vertical-align: top"> </p> <p> </p> <p> </p> <p> <strong>Florent Mazuir et al.</strong> </td> </tr> <tr> <td style="width:113.4px;border-bottom: solid black 1pt;vertical-align: top"> </td> <td style="width:179.6px;border-bottom: solid black 1pt;vertical-align: top"> </td> <td style="width:189px;border-bottom: solid black 1pt;vertical-align: top"> </td> <td style="width:132.27px;border-bottom: solid black 1pt;vertical-align: top"> </td> </tr> <tr> <td style="width:113.4px;text-align: left;vertical-align: middle;border-top: solid black 1pt;vertical-align: top"> <strong>PEDFIC1/2 OLE final results (LB)</strong> </td> <td style="width:179.6px;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;text-align: left;vertical-align: middle;border-top: solid black 1pt;vertical-align: top;text-align: left;vertical-align: middle"> <em>Poster, Abstract [5045]</em><br /><strong>Monday 18 November</strong><br />13:00–14:00<br />Poster Session IV </td> <td style="width:189px;text-align: left;vertical-align: middle;border-top: solid black 1pt;vertical-align: top"> Sustained, long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: Results from the PEDFIC2 Phase 3, open-label extension study </td> <td style="width:132.27px;text-align: left;vertical-align: middle;border-top: solid black 1pt;vertical-align: top"> <strong>Richard Thompson et al.</strong> </td> </tr> </table> <p align="justify"><strong><em>About Bylvay (odevixibat)</em></strong><br />Odevixibat is a once-daily non-systemic ileal bile acid transport (IBAT) inhibitor approved under the brand name Bylvay<sup>®</sup> in the U.S. as the first drug treatment option for patients 3 months of age and older living with cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC). BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific <em>ABCB11 </em>variants resulting in non-functional or complete absence of the bile salt export pump protein.</p> <p align="justify">Odevixibat was also approved in June 2021 in the E.U. under the brand name Bylvay<sup>®</sup>, as the first drug treatment option for all types of PFIC in patients aged 6 months or older. Bylvay has received orphan exclusivity for the treatment of PFIC in the U.S. and E.U. </p> <p align="justify">In June 2023 Bylvay was approved in the U.S. for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome (ALGS) and received orphan exclusivity for ALGS. In September 2024, odevixibat was approved in the E.U under the brand name Kayfanda<sup>®</sup> for the treatment of cholestatic pruritus in ALGS in patients aged 6 months or older.</p> <p align="justify"><strong>IMPORTANT SAFETY INFORMATION – U.S.</strong><br /><strong>Warnings and Precautions:</strong></p> <p align="justify"><strong>Liver Test Abnormalities</strong><br />Patients who enrolled in PFIC and ALGS clinical trials had abnormal liver tests at baseline. In clinical trials, treatment-emergent elevations of liver tests or worsening of liver tests relative to baseline values were observed. Most abnormalities included elevations in aspartate aminotransferase (AST), alanine transaminase (ALT) in PFIC and ALGS, and total and direct bilirubin in PFIC clinical trials. No patients permanently discontinued treatment due to liver test abnormalities.</p> <p align="justify">Obtain baseline liver tests and monitor during treatment. Dose reduction or treatment interruption may be required if abnormalities occur. For persistent or recurrent liver test abnormalities, consider treatment discontinuation.</p> <p align="justify">Permanently discontinue Bylvay if a patient progresses to portal hypertension or experiences a hepatic decompensation event.</p> <p align="justify"><strong>Diarrhea</strong><br />Diarrhea occurred in both PFIC and ALGS clinical trials in BYLVAY-treated patients at a rate greater than placebo treated patients. If diarrhea occurs with use of BYLVAY, monitor for dehydration and treat promptly. Treatment interruption or discontinuation may be required for persistent diarrhea with no alternate etiology.</p> <p align="justify"><strong>Fat-Soluble Vitamin (FSV) Deficiency</strong><br />Fat-soluble vitamins (FSV) include vitamin A, D, E, and K. PFIC and ALGS patients can have FSV deficiency at baseline, as part of their disease. BYLVAY may affect absorption of fat-soluble vitamins.</p> <p align="justify">Obtain baseline levels and monitor during treatment, along with any clinical manifestations. Supplement if deficiency is observed. If FSV deficiency persists or worsens despite FSV supplementation, discontinue treatment.</p> <p align="justify"><strong>ADVERSE REACTIONS</strong><br /><strong>ALGS:</strong> The most common adverse reactions (>5%) are diarrhea, abdominal pain, hematoma, and decreased weight.<br /><strong>PFIC:</strong> The most common adverse reactions (>2%) are diarrhea, liver test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency.</p> <p align="justify"><strong>DRUG INTERACTIONS</strong><br />For patients taking bile acid binding resins, take BYLVAY at least 4 hours before or 4 hours after administering, as bile acid binding resins may bind to and reduce BYLVAY efficacy.</p> <p align="justify"><strong>USE IN SPECIFIC POPULATIONS</strong><br />There are no human data on BYLVAY use in pregnant persons to establish a drug-associated risk of major birth defects, miscarriage, or adverse developmental outcomes. Based on findings from animal reproduction studies, BYLVAY may cause cardiac malformations when a fetus is exposed during pregnancy.</p> <p align="justify">There is a pregnancy safety study that monitors pregnancy outcomes in women exposed to BYLVAY during pregnancy. Pregnant women exposed to BYLVAY, or their healthcare providers, should report BYLVAY exposure by calling 1-855-463-5127.</p> <p align="justify"><strong>To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at +1-855-463-5127, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</strong></p> <p align="justify"><strong>Indications and Usage U.S.</strong><br />Bylvay is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in:<br />Patients 12 months of age and older with Alagille syndrome (ALGS)<br />Patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC)</p> <p align="justify"><strong>Limitation of use</strong><br />Bylvay may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein</p> <p align="justify"><strong>Please see full U.S. </strong><a href="https://www.globenewswire.com/Tracker?data=-BsbTtxpWPxUWWlD-hpFl_hy33x0zMsNUH2etXPZPX7Y1CL6N8KOWH2JB6JwpKfjhWl57v4SRXox0FJMQ7n4MayF22w9si39XS9Ra8srTfaE2XwtwXdpebNbficfzhJlE3nSNze46jxE9GABLxrfgucdOtp1-83UdzXA-pIzonbnRWt1x1RkSFk4_fuo1Xm-o7nbIkHYgVKheZCXDL1iV1Ft-Y0zNCfgvBHtXD5lC34UchVcffeUpKOs3hrsxg51hOxbHJSJQtWqt-n40Pq-qhONTYQGuGXZUz4SprCjzUQ=" rel="nofollow noopener" target="_blank" title=""><strong>Prescribing Information</strong></a><strong>.</strong></p> <p align="left"><strong>Indications of use E.U.</strong><br />Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older. <strong>Please see full E.U.</strong><a href="https://www.globenewswire.com/Tracker?data=OvISGXdtHCmHru1d2jWPoEHr4EiFqHjNt1WIvtAKDa-pHjmelQGSfuilDw4N_McUGHwckAIf-x6AKc8uHHR3Zfupgq3JclN-53l7A8HxaH4y2L80YhHDb8NAX6J8zrilmrTp04AiKgpAsbEFiquQYWB4IWOf2oZSM6Fe4DtzJG0gAHF2Gir_pB941MO9YKP1ak-QiAayJAtVazWec6ZzQw==" rel="nofollow noopener" target="_blank" title=""><strong> Prescribing Information</strong></a><strong>.</strong></p> <p align="justify">Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older. <strong>Please see full E.U.</strong><a href="https://www.globenewswire.com/Tracker?data=OvISGXdtHCmHru1d2jWPoEHr4EiFqHjNt1WIvtAKDa-ZzkTxYrIrF3TGhy75Rn9e7wrOnnHd06uLUct-hZiylpB4it2tBf1ItqBvnTZEClbJEXRn0plGlwx9b--aL_j5cUFkZBakootIV9wIeJ-dLzfj5ufzEA_Zjmj7tIKhTK5_QcXUfQG3Q3yhuQesuRJMNXjIs_Pw7rvArr8iwiXJ0Q==" rel="nofollow noopener" target="_blank" title=""><strong> Prescribing Information.</strong></a></p> <p align="center"><strong>ENDS</strong></p> <p align="justify"><strong>About PEDFIC 1 and 2</strong><br />PEDFIC 1 was a 24-week double-blind, randomized, placebo-controlled trial that evaluated the efficacy and tolerability of two doses of odevixibat in reducing pruritus and serum bile acid levels in children with PFIC 1 or 2. PEDFIC 2 is a 72-week open label extension trial, which consisted of children from PEDFIC 1 who received either Bylvay (cohort 1a) or placebo (cohort 1b) and a new cohort (2) of Bylvay-naïve patients of any age and PFIC subtype. </p> <p align="justify">PEDFIC is the largest, global, Phase III trial ever conducted in PFIC. PEDFIC 1 (NCT03566238) was a 24-week double-blind, randomized (1:1:1), placebo-controlled trial that evaluated the efficacy and tolerability of two doses of odevixibat in reducing pruritus and serum bile acid levels in children with PFIC 1 or 2. Participants were randomly allocated to receive placebo (n=20), odevixibat 40 μg/kg (n=23), or odevixibat 120 μg/kg (n=19) once a day. The results were published in <em>The Lancet</em>.<sup>3</sup></p> <p align="justify">PEDFIC 2 (NCT03659916), an open-label extension of PEDFIC 1, is a 72-week trial that aimed to evaluate the efficacy and tolerability of odevixibat 120 µg/kg once a day in patients with PFIC. Patients were divided into two cohorts: Cohort 1 (n=56) which consisted of children with PFIC 1 or 2 from PEDFIC 1 who received odevixibat (Cohort 1a: n= 37) or placebo (Cohort 1b: n=19), respectively, and Cohort 2 (n=60) which consisted of newly enrolled, odevixibat-naïve patients of any age and PFIC subtype. Interim results were published in <em>The Journal of Hepatology</em>.<sup>4</sup></p> <p align="left"><strong>About ASSERT and ASSERT-EXT</strong><br />ASSERT (NCT04674761) was a 24-week double-blind, randomized, placebo-controlled trial with an open-label long term extension. ASSERT evaluated the safety and efficacy of 120 µg /kg once-daily odevixibat vs placebo for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The trial enrolled 52 patients of any age with a genetically confirmed diagnosis of ALGS. The results were published in <em>The Lancet</em>.<sup>5</sup></p> <p align="justify">In ASSERT-EXT (NCT05035030), ASSERT’s ongoing open-label extension, all trial participants received 120 μg/kg of odevixibat once daily for 72-weeks after the double-blind treatment period completed. In both ASSERT and ASSERT-EXT, the investigators looked for changes in pruritus, serum bile acid concentrations, sleep, and treatment-emergent adverse events.</p> <p align="left"><strong>About Ipsen</strong><br />We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. </p> <p align="justify">Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. </p> <p align="justify">Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com </p> <p align="left"><strong>Ipsen Media contacts </strong></p> <p align="justify"><strong>Investors</strong></p> <ul type="disc"> <li style="margin-bottom:6pt;text-align:justify"><strong>Nicolas Bogler | + 33 6 52 19 98 92 </strong></li> </ul> <p align="justify"><strong>Media</strong></p> <ul type="disc"> <li style="margin-bottom:6pt;text-align:justify"><strong>Jennifer Smith-Parker | + 44 7487 75 71 00 | jennifer.smith-parker.ext@ipsen.com</strong></li> <li style="margin-bottom:6pt;text-align:justify"><strong>Rachel Reiff | + 1 908 616 1680 | rachel.reiff@ipsen.com</strong></li> <li style="margin-bottom:6pt;text-align:justify"><strong>Anna Gibbins | + 44 7717 80 19 00 | anna.gibbins@ipsen.com</strong></li> </ul> <p align="left"><strong>Disclaimers and/or Forward-Looking Statements</strong></p> <p align="justify"><strong>Ipsen</strong> <br />The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.</p> <p align="left"><strong>References</strong></p> <p align="left"><sup>1</sup>Thompson RJ, et al. Sustained, long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: Results from the PEDFIC2 phase 3, open-label extension study. Poster Abstract 5045, American Association for the Study of Liver Disease (AASLD). 2024<br /><sup>2</sup> Ovchinsky N., et al. ASSERT-EXT: Final data from an open-label, phase 3 study of odevixibat in patients with Alagille syndrome. Oral abstract Parallel ePoster 50. American Association for the Study of Liver Disease (AASLD). 2024<br /><sup>3</sup> Thompson RJ, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022. 7:830–842.<br /><sup>4</sup> Thompson RJ, et al. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis 2023. JHEP Rep. 5(8):100782.<br /><sup>5</sup> Ovchinsky N., et al. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT); a phase 3, double-blind, randomized, placebo-controlled trial. Lancet Gastroenterol / Hepatol. 2024 doi.org/10.1016/S2468-1253(24)00074-8.</p> <p id="gnw_attachments_section-header"> <strong>Attachment</strong> </p> <ul id="gnw_attachments_section-items"> <li> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tbxEJcm1ZdVirmtaKPphAc6WlnR_gp1l9UmyE81UK2yoYfVvBAv-dAWKPFTuCKMOfqALSjUIsQxa47hkVkVqiTlKEH4EtX2RrM66WSJbtdyxAkboT-R-T4Zn_sFc20mO2JL5fk4JBsThlLzqYD31lWpSKe33PqLBsF6BXIoDQiMgoWsoviXZ13kUgo2ghIDUuJ5nkvzYIVP_GLi7ybdimIzbAVg0qTv19OSnNeIBxdT7hhmE_TK2OhtA-ucbGuNoREbLbn8P7jMckpJZWKd2cl6tFq-8qKTLw_tzgMcPb9o=" title="Ipsen PR_Bylvay® (odevixibat) data shows sustained improvement in severe itch and sBA in PFIC and ALGS_181124" rel="nofollow noopener">Ipsen PR_Bylvay® (odevixibat) data shows sustained improvement in severe itch and sBA in PFIC and ALGS_181124</a> </li> </ul> <p><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://ml-eu.globenewswire.com/media/YWMwMjE1MDctMmQxNC00MTU1LWI1MmMtZmMxYjllOGJiMmMzLTEyNjgxMTY=/tiny/Ipsen-Pharma.png" /><noscript><img alt="" src='https://ml-eu.globenewswire.com/media/YWMwMjE1MDctMmQxNC00MTU1LWI1MmMtZmMxYjllOGJiMmMzLTEyNjgxMTY=/tiny/Ipsen-Pharma.png' /></noscript></p> </div> <div class="page-navigation bottom-page-nav"> <div class="next-prev-sect"> <nav class="navigation post-navigation" aria-label="Posts"> <h2 class="screen-reader-text">Post navigation</h2> <div class="nav-links"><div class="nav-previous"><a href="https://www.ipsen.com/press-releases/iqirvo-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-with-improvements-in-fatigue-and-pruritus-2982128/" rel="prev"><span class="prev-button">Previous</span></a></div><div class="nav-next"><a href="https://www.ipsen.com/press-releases/ipsen-and-biomunex-announce-exclusive-global-licensing-agreement-for-first-in-class-mait-cell-engager-in-immuno-oncology-2990251/" rel="next"><span class="next-button">Next</span></a></div></div> </nav> </div> </div> </div> <div class="right-post-side hidden">  <div class="side-panel-social-media"> </div>   <div class="side-panel-download-card"> </div>   <div class="side-panel-quicklink"> </div>   <div class="side-panel-comingevent"> </div>   <div class="side-panel-contact-card"> </div>  </div> <section class="p-slider related-story"> <div class="slider-heading-container"> <h2 class="slider-title">Related Press Releases</h2> </div>  <div class="slider-btns"> <button aria-label="Previous" aria-labelledby="glider-product-related-prev" role="button" title="Previous" class="glider-product-related-prev"> <span data-bg="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/blue-left-arrow.png" class="rocket-lazyload" style=""></span> </button> <button aria-label="Next" aria-labelledby="glider-product-related-next" role="button" title="Next" class="glider-product-related-next"> <span data-bg="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/blue-right-arrow.png" class="rocket-lazyload" style=""></span> </button> </div>  <div class="glider-contain multiple"> <div class="glider-product-related">  <a href="https://www.ipsen.com/press-releases/ipsen-delivers-solid-results-in-2024-driven-by-strong-performance-across-all-therapeutic-areas-and-provides-guidance-for-2025-3025567/"> <div class="product-box">  <div class="p-img-container"> <div class="p-img"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025" title="Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" ><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" alt="Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025" title="Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025" ></noscript> </div> </div>  <div class="p-box-text"> <button class="btn-link card-btn" style="background-color:#4e6e9a;"> Corporate </button> <span class="time-stamp">13 February 2025</span> <span class="time-stamp">6 mins read</span> <div class="text-div"> <h3>Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025</h3> </div> </div> </div> </a>  <a href="https://www.ipsen.com/press-releases/ipsen-and-biomunex-announce-exclusive-global-licensing-agreement-for-first-in-class-mait-cell-engager-in-immuno-oncology-2990251/"> <div class="product-box">  <div class="p-img-container"> <div class="p-img"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology" title="Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" ><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" alt="Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology" title="Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology" ></noscript> </div> </div>  <div class="p-box-text"> <button class="btn-link card-btn" style="background-color:#4e6e9a;"> Corporate </button> <span class="time-stamp">03 December 2024</span> <span class="time-stamp">6 mins read</span> <div class="text-div"> <h3>Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology</h3> </div> </div> </div> </a>  <a href="https://www.ipsen.com/press-releases/iqirvo-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-with-improvements-in-fatigue-and-pruritus-2982128/"> <div class="product-box">  <div class="p-img-container"> <div class="p-img"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus" title="Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" ><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" alt="Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus" title="Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus" ></noscript> </div> </div>  <div class="p-box-text"> <button class="btn-link card-btn" style="background-color:#4e6e9a;"> Corporate </button> <span class="time-stamp">15 November 2024</span> <span class="time-stamp">12 mins read</span> <div class="text-div"> <h3>Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus</h3> </div> </div> </div> </a>  <a href="https://www.ipsen.com/press-releases/ipsen-delivers-strong-sales-momentum-in-the-first-nine-months-of-2024-and-increases-its-full-year-guidance-2967449/"> <div class="product-box">  <div class="p-img-container"> <div class="p-img"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance" title="Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" ><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" alt="Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance" title="Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance" ></noscript> </div> </div>  <div class="p-box-text"> <button class="btn-link card-btn" style="background-color:#4e6e9a;"> Corporate </button> <span class="time-stamp">23 October 2024</span> <span class="time-stamp">4 mins read</span> <div class="text-div"> <h3>Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance</h3> </div> </div> </div> </a>  <a href="https://www.ipsen.com/press-releases/ipsen-receives-its-second-shingo-prize-for-operational-excellence-2962739/"> <div class="product-box">  <div class="p-img-container"> <div class="p-img"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ipsen receives its second Shingo Prize for operational excellence" title="Ipsen receives its second Shingo Prize for operational excellence" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" ><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" alt="Ipsen receives its second Shingo Prize for operational excellence" title="Ipsen receives its second Shingo Prize for operational excellence" ></noscript> </div> </div>  <div class="p-box-text"> <button class="btn-link card-btn" style="background-color:#4e6e9a;"> Corporate </button> <span class="time-stamp">14 October 2024</span> <span class="time-stamp">5 mins read</span> <div class="text-div"> <h3>Ipsen receives its second Shingo Prize for operational excellence</h3> </div> </div> </div> </a>  <a href="https://www.ipsen.com/press-releases/ipsens-kayfanda-odevixibat-approved-in-european-union-for-cholestatic-pruritus-in-alagille-syndrome-a-rare-liver-disease-2951259/"> <div class="product-box">  <div class="p-img-container"> <div class="p-img"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease" title="Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/09/17091122/PR_final.jpeg" ><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/09/17091122/PR_final.jpeg" alt="Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease" title="Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease" ></noscript> </div> </div>  <div class="p-box-text"> <button class="btn-link card-btn" style="background-color:#4e6e9a;"> Corporate </button> <span class="time-stamp">23 September 2024</span> <span class="time-stamp">8 mins read</span> <div class="text-div"> <h3>Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease</h3> </div> </div> </div> </a>  <a href="https://www.ipsen.com/press-releases/ipsens-iqirvo-elafibranor-approved-in-the-european-union-as-first-new-treatment-for-primary-biliary-cholangitis-in-nearly-a-decade-2949674/"> <div class="product-box">  <div class="p-img-container"> <div class="p-img"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade" title="Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/09/17091122/PR_final.jpeg" ><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/09/17091122/PR_final.jpeg" alt="Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade" title="Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade" ></noscript> </div> </div>  <div class="p-box-text"> <button class="btn-link card-btn" style="background-color:#4e6e9a;"> Corporate </button> <span class="time-stamp">20 September 2024</span> <span class="time-stamp">8 mins read</span> <div class="text-div"> <h3>Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade</h3> </div> </div> </div> </a>  <a href="https://www.ipsen.com/press-releases/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-in-advanced-neuroendocrine-tumors-2946663/"> <div class="product-box">  <div class="p-img-container"> <div class="p-img"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors" title="Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/09/17091122/PR_final.jpeg" ><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/09/17091122/PR_final.jpeg" alt="Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors" title="Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors" ></noscript> </div> </div>  <div class="p-box-text"> <button class="btn-link card-btn" style="background-color:#4e6e9a;"> Corporate </button> <span class="time-stamp">16 September 2024</span> <span class="time-stamp">9 mins read</span> <div class="text-div"> <h3>Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors</h3> </div> </div> </div> </a>  <a href="https://www.ipsen.com/press-releases/ipsen-provides-update-on-contact-02-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer-following-final-overall-survival-analysis-2946293/"> <div class="product-box">  <div class="p-img-container"> <div class="p-img"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis" title="Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" ><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" alt="Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis" title="Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis" ></noscript> </div> </div>  <div class="p-box-text"> <button class="btn-link card-btn" style="background-color:#4e6e9a;"> Corporate </button> <span class="time-stamp">15 September 2024</span> <span class="time-stamp">7 mins read</span> <div class="text-div"> <h3>Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis</h3> </div> </div> </div> </a>  <a href="https://www.ipsen.com/press-releases/ipsen-receives-chmp-positive-opinions-for-iqirvo-elafibranor-in-primary-biliary-cholangitis-and-kayfanda-odevixibat-in-alagille-syndrome-two-rare-cholestatic-liver-diseases-2919457/"> <div class="product-box">  <div class="p-img-container"> <div class="p-img"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases" title="Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" ><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg" alt="Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases" title="Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases" ></noscript> </div> </div>  <div class="p-box-text"> <button class="btn-link card-btn" style="background-color:#4e6e9a;"> Corporate </button> <span class="time-stamp">26 July 2024</span> <span class="time-stamp">12 mins read</span> <div class="text-div"> <h3>Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases</h3> </div> </div> </div> </a> </div> </div> </section> </div> </div> </div> </div><section role="contentinfo" class="footer-mainbg"> <div class="container"> <footer class="mainFootContainer"> <div class="container topFoot"> <div class="row"> <div class="col-lg-3 col-md-3 col-sm-6 col-12"> <div class="stock"> <p>IPN price</p> <div class="stock-price"> <p>€112.00</p> </div> <div class="stock-per-increase"> <p><i class="bi bi-arrow-up"></i> €0.70 (0.63%)</p> </div> </div> </div> <div class="col-lg-3 col-md-3 col-sm-6 col-6"> <ul class="list-unstyled footer-menu1"> <li class="mb-2 "> <a href="https://www.ipsen.com/press-release/" target="_self" >Media</a> </li> <li class="mb-2 "> <a href="https://www.ipsen.com/investors/" target="_self" >Investors</a> </li> <li class="mb-2 "> <a href="https://www.ipsen.com/partnering/" target="_self" >Partnering</a> </li> <li class="mb-2 "> <a href="https://www.ipsen.com/careers/" target="_self" >Careers</a> </li> </ul> </div> <div class="col-lg-3 col-md-3 col-sm-6 col-6"> <ul class="list-unstyled footer-menu2"> <li class="mb-2 "> <a href="https://www.ipsen.com/company/" target="_self" >Company</a> </li> <li class="mb-2 "> <a href="https://www.ipsen.com/sustainability/" target="_self" >Sustainability</a> </li> <li class="mb-2 "> <a href="https://www.ipsen.com/patients/" target="_self" >Patients</a> </li> <li class="mb-2 "> <a href="https://www.ipsen.com/stories/" target="_self" >Stories</a> </li> </ul> </div> <div class="col-lg-3 col-md-3 col-sm-6 col-6"> <ul class="list-unstyled footer-menu3"> <li class="mb-2 external-link "> <a href="https://www.ipsen.com/annualreport/" target="_blank" >Annual Report</a> </li> <li class="mb-2 normal-link "> <a href="https://www.ipsen.com/contact-us/" target="_self" >Contact us</a> </li> </ul> </div> </div> </div> <hr>  <div class="container copyFoot"> <div class="row"> <div class="col-lg-3 col-sm-3"> <div class="mb-4"> <a href="#"> <a href="https://www.ipsen.com/" class="custom-logo-link" rel="home"><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/12/07162335/Latest_Ipsen-logo_168x48.svg" class="custom-logo" alt="Latest_Ipsen logo" decoding="async" /></a> </a> <div class="social-media"> <a aria-label="LinkedIn, open in a new tab" href="https://www.linkedin.com/company/ipsen/" target="_blank"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" title="LinkedIn" alt="LinkedIn" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19050858/LinkedIn.png"><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19050858/LinkedIn.png" title="LinkedIn" alt="LinkedIn"></noscript> </a><a aria-label="Facebook, open in a new tab" href="https://www.facebook.com/Ipsengroup/" target="_blank"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" title="Facebook" alt="Facebook" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19053326/Facebook.png"><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19053326/Facebook.png" title="Facebook" alt="Facebook"></noscript> </a><a aria-label="Instagram, open in a new tab" href="https://www.instagram.com/ipsengroup" target="_blank"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" title="Instagram" alt="Instagram" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19053437/Instagram.png"><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19053437/Instagram.png" title="Instagram" alt="Instagram"></noscript> </a><a aria-label="Youtube, open in a new tab" href="https://www.youtube.com/IpsenBiopharmaceutical" target="_blank"> <img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" title="Youtube" alt="Youtube" data-lazy-src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19053540/Youtube-1.png"><noscript><img src="https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19053540/Youtube-1.png" title="Youtube" alt="Youtube"></noscript> </a> </div> </div> </div> <div class="col-lg-9 col-sm-9"> <ul class="copyLinks justify-content-end"> <li class=" "><a href="https://www.ipsen.com/terms-and-conditions/" target="_self" >Terms and Conditions</a></li> <li class=" "><a href="https://www.ipsen.com/cookie-policy/" target="_self" >Cookie Policy</a></li> <li class=" "><a href="https://www.ipsen.com/global-privacy-policy/" target="_self" >Global Privacy Policy</a></li> </ul> <div class="copyright justify-content-end"> <p>Copyright © Ipsen Pharma. All rights reserved - 2025</p> </div> </div>  <a data-bg="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/back-to-top.jpg" href="#btn-back-to-top" class="btn-floating rocket-lazyload" id="btn-back-to-top" aria-label="Back to top" style=""></a> </div> </div> </div>  </footer> </div> </section>   <div class="modal" id="siteexitModal" tabindex="-1" aria-labelledby="siteexitModalLabel" aria-hidden="true"> <div class="modal-dialog modal-dialog-centered"> <div class="modal-content"> <button class="close" aria-label="close" data-bs-dismiss="modal"> X </button> <div class="modal-body"><p>You are now leaving the Ipsen group website. To continue, please click on <b>Continue</b>?</p> </div> <div class="modal-footer">    <button type="button" class="btn btn-primary" role="button" data-bs-dismiss="modal"> <a href="#" id="continuelink" target="_blank">Continue</a> </button> <button type="button" class="btn btn-secondary" data-bs-dismiss="modal">No</button> </div> </div> </div> </div> </div>  <script> var _paq = _paq || []; _paq.push( ["setTrackingSource","wordpress","1.3.7"] ); </script> <script>document.body.classList.remove("no-js");</script><script src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/js/glider.min.js?ver=1739806752" id="carousal-glider-min-js"></script> <script data-minify="1" src="https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/js/multi-select.js?ver=1739443667" id="multi-select-js"></script> <script src="https://www.ipsen.com/wp-content/themes/ipsen-main/dist/js/slick.min.js?ver=1739806752" id="slick-min-js"></script> <script data-minify="1" src="https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/js/media-filter.js?ver=1739443667" id="media-filter-js"></script> <script src="https://www.ipsen.com/wp-includes/js/imagesloaded.min.js?ver=5.0.0" id="imagesloaded-js"></script> <script src="https://www.ipsen.com/wp-includes/js/masonry.min.js?ver=4.2.2" id="masonry-js"></script> <script src="https://www.ipsen.com/wp-includes/js/jquery/jquery.masonry.min.js?ver=3.1.2b" id="jquery-masonry-js"></script> <script id="wpgmp-google-map-main-js-extra"> var wpgmp_local = {"select_radius":"Select Radius","search_placeholder":"Enter address or latitude or longitude or title or city or state or country or postal code here...","select":"Select","select_all":"Select All","select_category":"Select Category","all_location":"All","show_locations":"Show Locations","sort_by":"Sort by","wpgmp_not_working":"not working...","place_icon_url":"https:\/\/www.ipsen.com\/wp-content\/plugins\/wp-google-map-gold\/assets\/images\/icons\/","wpgmp_location_no_results":"No results found.","wpgmp_route_not_avilable":"Route is not available for your requested route.","img_grid":"<span class='span_grid'><a class='wpgmp_grid'><img src='https:\/\/www.ipsen.com\/wp-content\/plugins\/wp-google-map-gold\/assets\/images\/grid.png'><\/a><\/span>","img_list":"<span class='span_list'><a class='wpgmp_list'><img src='https:\/\/www.ipsen.com\/wp-content\/plugins\/wp-google-map-gold\/assets\/images\/list.png'><\/a><\/span>","img_print":"<span class='span_print'><a class='wpgmp_print' data-action='wpgmp-print'><img src='https:\/\/www.ipsen.com\/wp-content\/plugins\/wp-google-map-gold\/assets\/images\/print.png'><\/a><\/span>","hide":"Hide","show":"Show","start_location":"Start Location","start_point":"Start Point","radius":"Radius","end_location":"End Location","take_current_location":"Take Current Location","center_location_message":"Your Location","driving":"Driving","bicycling":"Bicycling","walking":"Walking","transit":"Transit","metric":"Metric","imperial":"Imperial","find_direction":"Find Direction","miles":"Miles","km":"KM","show_amenities":"Show Amenities","find_location":"Find Locations","locate_me":"Locate Me","prev":"Prev","next":"Next","ajax_url":"https:\/\/www.ipsen.com\/wp-admin\/admin-ajax.php","nonce":"6933f55062","wpgmp_country_specific":"","wpgmp_countries":"","wpgmp_assets":"https:\/\/www.ipsen.com\/wp-content\/plugins\/wp-google-map-gold\/assets\/js\/"}; </script> <script data-minify="1" src="https://www.ipsen.com/wp-content/cache/min/0/wp-content/plugins/wp-google-map-gold/assets/js/minified/maps.js?ver=1739443667" id="wpgmp-google-map-main-js"></script> <script src="https://maps.google.com/maps/api/js?key=AIzaSyBPB4Dg7WynQl-yf_SIDrPNH1Iw0FHjB-A&callback=wpgmpInitMap&libraries=geometry%2Cplaces%2Cdrawing&language=en&ver=5.7.3" id="wpgmp-google-api-js"></script> <script src="https://www.ipsen.com/wp-content/plugins/wp-google-map-gold/assets/js/minified/wpgmp_frontend.min.js?ver=5.7.3" id="wpgmp-frontend-js"></script> <script id="rocket-browser-checker-js-after"> "use strict";var _createClass=function(){function defineProperties(target,props){for(var i=0;i<props.length;i++){var descriptor=props[i];descriptor.enumerable=descriptor.enumerable||!1,descriptor.configurable=!0,"value"in descriptor&&(descriptor.writable=!0),Object.defineProperty(target,descriptor.key,descriptor)}}return function(Constructor,protoProps,staticProps){return protoProps&&defineProperties(Constructor.prototype,protoProps),staticProps&&defineProperties(Constructor,staticProps),Constructor}}();function _classCallCheck(instance,Constructor){if(!(instance instanceof Constructor))throw new TypeError("Cannot call a class as a function")}var RocketBrowserCompatibilityChecker=function(){function RocketBrowserCompatibilityChecker(options){_classCallCheck(this,RocketBrowserCompatibilityChecker),this.passiveSupported=!1,this._checkPassiveOption(this),this.options=!!this.passiveSupported&&options}return _createClass(RocketBrowserCompatibilityChecker,[{key:"_checkPassiveOption",value:function(self){try{var options={get passive(){return!(self.passiveSupported=!0)}};window.addEventListener("test",null,options),window.removeEventListener("test",null,options)}catch(err){self.passiveSupported=!1}}},{key:"initRequestIdleCallback",value:function(){!1 in window&&(window.requestIdleCallback=function(cb){var start=Date.now();return setTimeout(function(){cb({didTimeout:!1,timeRemaining:function(){return Math.max(0,50-(Date.now()-start))}})},1)}),!1 in window&&(window.cancelIdleCallback=function(id){return clearTimeout(id)})}},{key:"isDataSaverModeOn",value:function(){return"connection"in navigator&&!0===navigator.connection.saveData}},{key:"supportsLinkPrefetch",value:function(){var elem=document.createElement("link");return elem.relList&&elem.relList.supports&&elem.relList.supports("prefetch")&&window.IntersectionObserver&&"isIntersecting"in IntersectionObserverEntry.prototype}},{key:"isSlowConnection",value:function(){return"connection"in navigator&&"effectiveType"in navigator.connection&&("2g"===navigator.connection.effectiveType||"slow-2g"===navigator.connection.effectiveType)}}]),RocketBrowserCompatibilityChecker}(); </script> <script id="rocket-preload-links-js-extra"> var RocketPreloadLinksConfig = {"excludeUris":"\/(?:.+\/)?feed(?:\/(?:.+\/?)?)?$|\/(?:.+\/)?embed\/|http:\/\/(\/%5B\/%5D+)?\/(index.php\/)?(.*)wp-json(\/.*|$)|\/refer\/|\/go\/|\/recommend\/|\/recommends\/","usesTrailingSlash":"1","imageExt":"jpg|jpeg|gif|png|tiff|bmp|webp|avif|pdf|doc|docx|xls|xlsx|php","fileExt":"jpg|jpeg|gif|png|tiff|bmp|webp|avif|pdf|doc|docx|xls|xlsx|php|html|htm","siteUrl":"https:\/\/www.ipsen.com","onHoverDelay":"100","rateThrottle":"3"}; </script> <script id="rocket-preload-links-js-after"> (function() { "use strict";var r="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},e=function(){function i(e,t){for(var n=0;n<t.length;n++){var i=t[n];i.enumerable=i.enumerable||!1,i.configurable=!0,"value"in i&&(i.writable=!0),Object.defineProperty(e,i.key,i)}}return function(e,t,n){return t&&i(e.prototype,t),n&&i(e,n),e}}();function i(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}var t=function(){function n(e,t){i(this,n),this.browser=e,this.config=t,this.options=this.browser.options,this.prefetched=new Set,this.eventTime=null,this.threshold=1111,this.numOnHover=0}return e(n,[{key:"init",value:function(){!this.browser.supportsLinkPrefetch()||this.browser.isDataSaverModeOn()||this.browser.isSlowConnection()||(this.regex={excludeUris:RegExp(this.config.excludeUris,"i"),images:RegExp(".("+this.config.imageExt+")$","i"),fileExt:RegExp(".("+this.config.fileExt+")$","i")},this._initListeners(this))}},{key:"_initListeners",value:function(e){-1<this.config.onHoverDelay&&document.addEventListener("mouseover",e.listener.bind(e),e.listenerOptions),document.addEventListener("mousedown",e.listener.bind(e),e.listenerOptions),document.addEventListener("touchstart",e.listener.bind(e),e.listenerOptions)}},{key:"listener",value:function(e){var t=e.target.closest("a"),n=this._prepareUrl(t);if(null!==n)switch(e.type){case"mousedown":case"touchstart":this._addPrefetchLink(n);break;case"mouseover":this._earlyPrefetch(t,n,"mouseout")}}},{key:"_earlyPrefetch",value:function(t,e,n){var i=this,r=setTimeout(function(){if(r=null,0===i.numOnHover)setTimeout(function(){return i.numOnHover=0},1e3);else if(i.numOnHover>i.config.rateThrottle)return;i.numOnHover++,i._addPrefetchLink(e)},this.config.onHoverDelay);t.addEventListener(n,function e(){t.removeEventListener(n,e,{passive:!0}),null!==r&&(clearTimeout(r),r=null)},{passive:!0})}},{key:"_addPrefetchLink",value:function(i){return this.prefetched.add(i.href),new Promise(function(e,t){var n=document.createElement("link");n.rel="prefetch",n.href=i.href,n.onload=e,n.onerror=t,document.head.appendChild(n)}).catch(function(){})}},{key:"_prepareUrl",value:function(e){if(null===e||"object"!==(void 0===e?"undefined":r(e))||!1 in e||-1===["http:","https:"].indexOf(e.protocol))return null;var t=e.href.substring(0,this.config.siteUrl.length),n=this._getPathname(e.href,t),i={original:e.href,protocol:e.protocol,origin:t,pathname:n,href:t+n};return this._isLinkOk(i)?i:null}},{key:"_getPathname",value:function(e,t){var n=t?e.substring(this.config.siteUrl.length):e;return n.startsWith("/")||(n="/"+n),this._shouldAddTrailingSlash(n)?n+"/":n}},{key:"_shouldAddTrailingSlash",value:function(e){return this.config.usesTrailingSlash&&!e.endsWith("/")&&!this.regex.fileExt.test(e)}},{key:"_isLinkOk",value:function(e){return null!==e&&"object"===(void 0===e?"undefined":r(e))&&(!this.prefetched.has(e.href)&&e.origin===this.config.siteUrl&&-1===e.href.indexOf("?")&&-1===e.href.indexOf("#")&&!this.regex.excludeUris.test(e.href)&&!this.regex.images.test(e.href))}}],[{key:"run",value:function(){"undefined"!=typeof RocketPreloadLinksConfig&&new n(new RocketBrowserCompatibilityChecker({capture:!0,passive:!0}),RocketPreloadLinksConfig).init()}}]),n}();t.run(); }()); </script> <script data-minify="1" src="https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/dist/js/custom.js?ver=1739443667" id="ipsenmain-customjs-js"></script> <script id="book-meeting-js-extra"> var ajax_var = {"url":"https:\/\/www.ipsen.com\/wp-admin\/admin-ajax.php","nonce":"b752d1fe4a"}; </script> <script data-minify="1" src="https://www.ipsen.com/wp-content/cache/min/0/wp-content/themes/ipsen-main/template-parts/ipsen-blocks/book-meeting/js/book-meeting.js?ver=1739443667" id="book-meeting-js"></script> <script src="https://www.google.com/recaptcha/api.js?ver=6.7.2" id="google-recaptcha-js"></script> <script>window.lazyLoadOptions=[{elements_selector:"img[data-lazy-src],.rocket-lazyload",data_src:"lazy-src",data_srcset:"lazy-srcset",data_sizes:"lazy-sizes",class_loading:"lazyloading",class_loaded:"lazyloaded",threshold:300,callback_loaded:function(element){if(element.tagName==="IFRAME"&&element.dataset.rocketLazyload=="fitvidscompatible"){if(element.classList.contains("lazyloaded")){if(typeof window.jQuery!="undefined"){if(jQuery.fn.fitVids){jQuery(element).parent().fitVids()}}}}}},{elements_selector:".rocket-lazyload",data_src:"lazy-src",data_srcset:"lazy-srcset",data_sizes:"lazy-sizes",class_loading:"lazyloading",class_loaded:"lazyloaded",threshold:300,}];window.addEventListener('LazyLoad::Initialized',function(e){var lazyLoadInstance=e.detail.instance;if(window.MutationObserver){var observer=new MutationObserver(function(mutations){var image_count=0;var iframe_count=0;var rocketlazy_count=0;mutations.forEach(function(mutation){for(var i=0;i<mutation.addedNodes.length;i++){if(typeof mutation.addedNodes[i].getElementsByTagName!=='function'){continue} if(typeof mutation.addedNodes[i].getElementsByClassName!=='function'){continue} images=mutation.addedNodes[i].getElementsByTagName('img');is_image=mutation.addedNodes[i].tagName=="IMG";iframes=mutation.addedNodes[i].getElementsByTagName('iframe');is_iframe=mutation.addedNodes[i].tagName=="IFRAME";rocket_lazy=mutation.addedNodes[i].getElementsByClassName('rocket-lazyload');image_count+=images.length;iframe_count+=iframes.length;rocketlazy_count+=rocket_lazy.length;if(is_image){image_count+=1} if(is_iframe){iframe_count+=1}}});if(image_count>0||iframe_count>0||rocketlazy_count>0){lazyLoadInstance.update()}});var b=document.getElementsByTagName("body")[0];var config={childList:!0,subtree:!0};observer.observe(b,config)}},!1)</script><script data-no-minify="1" async src="https://www.ipsen.com/wp-content/plugins/wp-rocket/assets/js/lazyload/17.8.3/lazyload.min.js"></script> <script type="text/javascript"> $(".wechat-container").hover(function(){ $('.icon-Wechat-qr').show(10); }, function(){ $('.icon-Wechat-qr').hide(10); }) var home_url = "https://www.ipsen.com"; jQuery(".searchDropdown").click(function(){ jQuery(".searchInput").focus(); }); jQuery(".searchDropdownMobile").click(function(){ jQuery(".searchInput").focus(); }); var searchTimeout; function show_results(val){ let list = ''; let category_name = jQuery("#cat").val(); if( category_name === '' ){ category_name = jQuery("#cat_list").val(); } let currentstore = jQuery("#currentstore").val(); if(val == "" || val.length <= 0){ jQuery(".defaultsuggestion").show(); } clearTimeout(searchTimeout); searchTimeout = setTimeout(function() { if(val.length>= 3){ searchXHR = $.ajax({ url : 'https://www.ipsen.com/wp-admin/admin-ajax.php', type : 'post', data : {lib_data_id: val, currentstore: currentstore, category_name: category_name, action:'add_to_search' }, success : function( response ) { response = jQuery.parseJSON(response); if(response.length > 0){ for (i=0; i<response.length; i++) { // list += '<li><a href="javascript:void(0);">' + response[i]['post_title'] + '</a></li>'; list += '<li><a target="_blank" href="https://www.ipsen.com/?p=' + response[i]['ID'] + '">' + response[i]['post_title'] + '</a></li>'; } //res.innerHTML = '<ul>' + list + '</ul>'; }else{ list ='No Records Found!'; } jQuery(".defaultsuggestion").hide(); //document.getElementsByClassName("autoSuggestion").innerHTML = '<ul>' + list + '</ul>'; jQuery(".autoSuggestion").html('<ul aria-label="No Records Found!">' + list + '</ul>'); }, complete: function () { jQuery('.loader').hide(); }, }); }else{ jQuery(".autoSuggestion").html(''); jQuery(".defaultsuggestion").show(); } }, 500); // Wait 500ms before sending the AJAX request } jQuery(".go-back-menu").click(function(){ jQuery(".dropdown-menu").removeClass("show"); }); jQuery(".go-country-back").click(function(){ jQuery(".dropdown-menu-end").removeClass("show"); jQuery(".nav-link").removeClass("show"); }); function get_download_item(){ var otp = ""; // Traverse through all inputs jQuery(".library-input").each(function(){ otp = (this.checked ? jQuery(this).val() : ""); // otp += ','; filename_download_link_ // let id = jQuery(this).val(); if( otp != ""){ // alert(otp); let downloadlink = jQuery("#download_link_"+otp).val(); console.log(otp); let fileExtension = downloadlink.substr((downloadlink.lastIndexOf('.') + 1)); console.log(downloadlink); console.log(fileExtension); let filename = jQuery("#filename_"+otp).val(); let filetype = jQuery("#filetype_"+otp).val(); let filesubtype = jQuery("#filesubtype_"+otp).val(); if (filetype != 'video'){ var link = document.createElement('a'); // link.download = 'img_pdf'+filename; // link.href = downloadlink; // document.body.appendChild(link); // link.target = "_blank"; // link.click(); // document.body.removeChild(link); // console.log(link); console.log('----------'); // console.log(filename); // link.remove(); link.setAttribute('href', downloadlink); //link.setAttribute('download', 'download.pdf'); link.setAttribute('download', 'download.'+fileExtension); link.setAttribute('target', '_blank'); document.body.appendChild(link); link.click(); document.body.removeChild(link); } if (filetype == 'video'){ var link = document.createElement('a'); link.href = downloadlink; link.download = filename + new Date() + ".mp4"; link.target = "_blank"; document.body.appendChild(link); link.click(); document.body.removeChild(link); console.log(link); console.log('----------'); console.log(filename); link.remove(); } } } ); } function get_model_item(mid){ jQuery("#loadingmodel").show(); jQuery(".media-library").show(); var filesize = jQuery("#filesize_"+mid).val(); var downloadlink = jQuery("#download_link_"+mid).val(); jQuery.ajax({ url : 'https://www.ipsen.com/wp-admin/admin-ajax.php', type : 'post', data : {lib_data_id: mid,filesize:filesize,downloadlink:downloadlink, action:'model_media'}, success : function( response ) { jQuery(".media-library").show(); jQuery("#loadingmodel").hide(); jQuery("#load_model").html(response); }, complete: function () { jQuery("#loadingmodel").hide(); }, }); } function get_load_model_item(mid){ jQuery("#loadingmodel").show(); jQuery(".media-library").show(); var filesize = jQuery("#filesize_carou_"+mid).val(); var downloadlink = jQuery("#download_link_carou_"+mid).val(); jQuery.ajax({ url : 'https://www.ipsen.com/wp-admin/admin-ajax.php', type : 'post', data : {lib_data_id: mid,filesize:filesize,downloadlink:downloadlink, action:'model_media'}, success : function( response ) { jQuery("#load_model").html(response); }, complete: function () { jQuery("#loadingmodel").hide(); }, }); } //below go-back-button click event for mobile device jQuery(".go-back-menu").click(function(){ jQuery(".nav-link.cool-link").removeClass("show"); }); function getFirstPath(url) { try { // Prepend "http://" if the protocol is missing if (!/^https?:\/\//i.test(url)) { url = 'http://' + url; } var urlObject = new URL(url); var pathname = urlObject.pathname; var pathSegments = pathname.split('/'); var firstPath = pathSegments[1]; return firstPath || null; } catch (error) { // Invalid URL or other error occurred return null; } } function addExternalLinkClass(){ // allSites = ['us','annualreport','mx','anz','de','be','nl','it','gr','japan']; var jsonString = document.getElementById('ipn-all-sites').value; var allSites = JSON.parse(jsonString); jQuery('a').filter(function() { if(this.hostname == 'wave-eu-west-1.s3.eu-west-1.amazonaws.com' || this.hostname == 'ml-eu.globenewswire.com' || this.href.includes('ml-eu.globenewswire.com') || this.href.includes('https://www.gllocation.pathnameobenewswire.com') || this.href === '#' || this.href.includes('javascript:void(0);') || this.href.startsWith('tel:') || this.href.startsWith('mailto:') || !this.hasAttribute('href') || this.href.endsWith('.pdf') || this.href.startsWith("https://www.ipsen.com/websites/ipsen_com_v2") ) { return false; } //If external site if(this.hostname !== location.hostname){ return true; } var targetUrl = this.href; var currentUrl = window.location.href; var targetFirstPath = getFirstPath(targetUrl); var currentFirstPath = getFirstPath(currentUrl); if( jQuery.inArray(currentFirstPath, allSites) !== -1 || jQuery.inArray(targetFirstPath, allSites) !== -1 ) { return targetFirstPath !== currentFirstPath } else { return false; } }).addClass("externallink"); } //below go-back-button click event for mobile device jQuery(document).on("click",".externallink", function(){ var modal = new bootstrap.Modal(document.getElementById('siteexitModal')); modal.show(); var linkurl = this.href; document.getElementById('continuelink').href = linkurl; return false; }); addExternalLinkClass(); </script> </body> </html>

CINXE.COM

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS